American College of Gastroenterology
WCOG at ACG2017 Scientific Meeting and Postgraduate Course
October 13-18, 2017, Orlando, FL

Practice Management Course  Friday, October 13, 2017
“Future World: Taking Ownership During Changing Times”

Course Co-Directors: Ralph D. McKibbin, MD, FACG, and Louis J. Wilson, MD, FACG
Healthcare delivery is transforming at an accelerating rate, but opportunities in the field of gastroenterology remain strong for physicians to claim ownership of their practices and their careers. Physician leadership and ownership will be even more important during these changing times, but that alone will not be enough for success. Faculty of the 2017 Practice Management Course, many from private practices, delivered presentations focusing on new ways to improve operations, enhance productivity, and guarantee success for one’s practice.

SESSION 1: THE BIG PICTURE IN A SMALL WORLD

Presidential Address: Physician Wellness: A Critical Mission
Carol A. Burke, MD, FACG
Define physician wellness, review the impact of physician wellness on outcomes, and outline ACG’s commitment to physician wellness.

Market Forces in GI Practice: Is Ownership a Vanishing Dream?
Carol D. Koscheski, MD, FACG
Describe the trends in healthcare delivery that will alter private practice, understand how physician ownership is central to the future of health care, and identify ownership opportunities in the future.

Quality Reporting Update: The Happy Side of MIPS
Costas H. Kefalas, MD, MMM, FACG
Evaluate the current status of the Merit-based Incentive Payment System (MIPS) and the opportunities for positive change in private practices.

SESSION 2: VENTURES AND ENTREPRENEURSHIP

Physician Entrepreneurs in GI Medicine
Ralph D. McKibbin, MD, FACG
Recognize entrepreneurship and the role of clinical gastroenterologists in practice innovation, inspire creative thinking for practice improvements, and outline examples of successful entrepreneurs.

James A. Turner, Jr., MBA, MHA
List the steps to creating a business plan, highlight qualities that make a plan strong, and describe why entrepreneurship is vital for the future of private practice using examples applicable to gastroenterologists.

True Adventures in Ancillaries
Reed B. Hogan, II, MD
Harry E. Sarles, Jr., MD, FACG
Identify the vital importance of ancillary services to the profitability of private practice, specify the major opportunities in gastroenterology, and use real-life examples to demonstrate success in ancillary services.

SESSION 3: THE CIRCLE OF LIFE IN YOUR PRACTICE

Advanced Use of Advanced Practice Providers
Colleen M. Schmitt, MD, MHS, FACG
Outline the evolving use of advanced practice providers in private practice gastroenterology, describe the obstacles to incorporating them into practice, and specify opportunities for mutual success.

Stop the Leaks: Solving Your Overhead Problems
James A. Turner, Jr., MBA, MHA
Identify major overhead categories and diagram an approach to reducing overhead while improving productivity.

Med Law Update: Healthcare Fraud and Other Risk Areas
Richard E. Moses, DO, JD, FACG
Describe the implications of federal anti-kickback laws and other hot areas of Office of Inspector General prosecutions in health care as they relate to medical directorships, practice ownership, and partnership in gastroenterology, and outline methods to avoid legal problems.

Audit Proof Your Practice
David J. Zetter, PHR, SHRM-CP, CHCC, CPCO, CPC, COC, PCS, FCS, CHBC, CMUP, PESC, CMAP
Discuss the major categories of RAC audit risk for private practices and establish processes that reduce that risk and prepare practices for potential RAC audits.
SESSION 4: ENGAGING PATIENTS AND IMPROVING CARE

Transforming Patient Engagement to Close Care Gaps
Lawrence R. Kosinski, MD, MBA, FACG
Illustrate the transformation of patient engagement from a focus on patient satisfaction surveys to population management and identifying solutions to care gaps that also improve practice performance.

Improving the Customer Journey
Michael S. Morelli, MD, CPE, FACG
Demonstrate how mapping a customer’s experience can be used to improve the performance of private practice.

Effective Patient Education and Communication
Harish K. Gagneja, MD, FACG
Recognize the importance of patient education in clinical practice, compare and contrast current methods of patient education, and identify the most effective communication platforms.

Reputation Management
Ken J. Brown, MD
Define the differences between reputation management and patient satisfaction surveys, and evaluate the tools available to manage the community reputation of a practice.

SESSION 5: YOUR PRACTICE CULTURE

Partnership and Conflict
Jay N. Yepuri, MD, MS
Identify major areas of conflict between partners in private practice, describe the dangers of these conflicts to successful physician ownership and leadership, and outline methods to avoid and solve these conflicts.

Cultivating Ownership by Developing New Leaders in Your Group
Irving M. Pike, MD, FACG
Recognize the importance of leadership development in a private practice partnership, outline challenges and opportunities, highlight the role of professional societies, and demonstrate how practice projects can be used to involve partners and guarantee success.

Culture Change and Transition in Your Practice
Louis J. Wilson, MD, FACG
Define corporate culture and its importance to the future of a business, and discuss recommendations for maintaining positive corporate culture during transitions.
American College of Gastroenterology
WCOG at ACG2017 Scientific Meeting and Postgraduate Course
October 13-18, 2017, Orlando, FL

GI Pathophysiology Course
Friday, October 13, 2017

Course Directors: Darwin L. Conwell, MD, MS, and Ikuo Hirano, MD, FACG
This half-day course illustrates the mechanisms behind novel diagnostic strategies, helps to formulate a plan using appropriate testing methodologies, and offers practical implementation strategies.

Current and Future Clinical Applications of the Microbiome in GI Disease
Eamonn M. M. Quigley, MD, MACG
Assess the role of the enteric microbiome and metabolome and the potential use of probiotics in various GI disorders including C. difficile infection.

Scientific Basis for Novel Immunologic Approaches to IBD
Miguel D. Regueiro, MD, FACG
Apply concepts regarding the immunologic basis for novel biologic therapies to the management of IBD.

When, Why, and How to Apply Molecular and Genetic Testing to Colon Polyps and Cancer
Elena M. Stoffel, MD, MPH
Formulate an approach to the use of molecular and genetic testing in the evaluation and management of colon polyps and cancer.

Celiac Disease: Novel Therapeutic Approaches Beyond Gluten Withdrawal
Peter H. R. Green, MD, FACG
Identify the mechanisms behind novel diagnostic strategies and pharmacologic approaches for patients with celiac disease.

Management of Eosinophilic Esophagitis: Food Allergy or Acid Reflux?
Nirmala Gonsalves, MD
Describe the rationale and practical approach for using proton pump inhibitors and elimination diet therapies in the management of eosinophilic esophagitis.

Interpretation and Therapeutic Implications of Physiologic Testing in the Management of Refractory Reflux
John O. Clarke, MD
Identify the pearls and pitfalls in the use of motility, impedance, and pH testing in the assessment of patients with refractory reflux disease.

Mechanistic Underpinnings for the Management of Refractory Constipation
Darren M. Brenner, MD
Apply concepts regarding the physiologic basis of constipation to inform therapeutic decisions for patients with refractory constipation.
What's New in GI Pharmacology Course
Friday, October 13, 2017

Course Directors: Brooks D. Cash, MD, FACG, and Scott M. Tenner, MD, MS, MPH, JD, FACG

ACG’s What’s New in GI Pharmacology Course provides an intensive review of key GI pharmacology, including comparisons and contrasts between conventional and emerging pharmacological treatment options for a variety of GI disorders. The course is designed primarily for physicians in GI/hepatology, as well as physician assistants, nurse practitioners, and other advanced practice healthcare professionals interested in the latest information on state-of-the-art treatment of these illnesses.

IBD: The First Visit
Francis A. Farraye, MD, MSc, FACG
Review appropriate tests, vaccinations, referrals, and medications needed for patients with IBD on their first visit, depending on disease activity.

Routine and Emergent Anticoagulation Management in the Periendoscopic Period
David A. Greenwald, MD, FACG
Define the use and management of new anticoagulation medications and reversal agents in patients undergoing endoscopy or experiencing GI bleeding.

Rational PPI Therapy in the Era of Concern
Kenneth R. DeVault, MD, FACG
Describe the evidence found in new studies that questions the safety of long-term use of PPIs.

Practical Guide to HCV Therapy in 2017
Jorge L. Herrera, MD, MACG
Compare the safety, efficacy, and prescribing guidelines of the new direct-acting antagonists used to treat chronic hepatitis C.

Pharmacologic Approach to IBS: Beyond Diet and Fiber
Brooks D. Cash, MD, FACG
Assess current pharmacologic treatment options for functional GI disorders.

Medical Management of Fatty Liver Disease
Philip K. Henderson, DO
Discuss the issues and interventions currently available for the management of fatty liver disease, with a focus on available pharmacologic approaches.

Medication Use in Pregnancy
Sunanda V. Kane, MD, MSPH, FACG
Determine available pharmacological therapies that are safe for treatment of GI disorders in the pregnant patient.

Pharmacologic Treatment of Pancreatic Disorders
Scott M. Tenner, MD, MS, MPH, JD, FACG
Differentiate the latest options for the prevention and treatment of acute and chronic pancreatitis.
American College of Gastroenterology
WCOG at ACG2017 Scientific Meeting and Postgraduate Course
October 13-18, 2017, Orlando, FL

Annual Postgraduate Course  Saturday, October 14 and Sunday, October 15, 2017
“Global Approach to Optimal Management of GI Disorders”

Course Directors: Geoffrey Metz, AM, FRACP, MD, FRCP, FACP, Aasma Shaukat, MD, MPH, FACG, and Marcelo F. Vela, MD, MSCR, FACG

Staying informed of new and emerging advancements in the field of gastroenterology, combined with the volume of patients increasing as the population ages, can challenge any clinical gastroenterologist and advanced practitioner to deliver his or her best patient care. Focused on a world-view of GI disease for the World Congress of Gastroenterology at ACG2017 (WCOG at ACG2017), the popular Postgraduate Course will provide updates on a variety of gastroenterology and hepatology subjects including colon, IBD, small bowel and functional disorders, endoscopic emergencies, quality metrics in GI, obesity, pancreaticobiliary, liver disease, esophagus and stomach, liver disease, and motility. Expert faculty provide scientific presentations on the latest topics in GI and liver clinical care. Learn what is on the horizon that may impact your practice as experts address a global approach to managing GI disorders. The program is designed primarily for clinicians in GI/hepatology, as well as physician assistants, nurse practitioners, and other advanced practice healthcare professionals interested in a scientifically sound approach to the management of GI and liver illnesses.

Saturday, October 14, 2017

SESSION 1A: Updates in Gastroduodenal Disorders
Moderators: Brian E. Lacy, MD, PhD, FACG, and Geoffrey Metz, AM, FRACP, MD, FRCP, FACP

Management of Functional Dyspepsia
Paul Moayyedi, MBChB, PhD, MPH, FACG
Evaluate the latest guidelines and evidence on management of functional dyspepsia.

Updates in Pharmacological Therapy for IBS
Brian E. Lacy, MD, PhD, FACG
Discuss the selection of appropriate pharmacological agents for the treatment of IBS.

Dietary and Other Non-pharmacological Management Options for IBS
Peter R. Gibson, MD
Identify the role of dietary and mental health-based therapies for IBS.

Wheat Sensitivity: Is it Celiac Disease?
Geoffrey Metz, AM, FRACP, MD, FRCP, FACP
Explain the practical approach and guidelines for diagnosing and treating patients with wheat sensitivity disorders, and discuss the role of vaccines for celiac disease.

ACG’S DAVID SUN LECTURE
Screening and Surveillance of Barrett’s Esophagus: Where Are We Now and What Does the Future Hold?
Gary W. Falk, MD, MS, FACG
Define current best practices and review upcoming options for screening and surveillance of Barrett’s esophagus.

SESSION 1B: Complex Issues in Inflammatory Bowel Disease
Moderators: Uma Mahadevan, MD, FACG, and Gerhard Rogler, MD, PhD

Loss of Response to Anti-TNFs – What Should I Do Next?
Uma Mahadevan, MD, FACG
Describe the natural history and treatment options for patients failing anti-TNF therapy.
Enhanced Imaging for Detection of Dysplasia in IBD Surveillance
Ralf Kiesslich, MD, PhD
Review the optimal approach to detection and management of dysplasia in IBD surveillance.

Use of Anti-TNF Antibodies, Drug Levels, and Other Serological Markers in IBD
Gerhard Rogler, MD, PhD
Enumerate the indications and clinical applications of anti-TNF antibodies and other prognostic serological markers for IBD management.

Diet, FMT, and Other Non-pharmacological Management Options for IBD
Charles N. Bernstein, MD, FACG
Discuss the role of diet, use of FMT, and other non-pharmacological therapies in the management of IBD.

SATURDAY LEARNING LUNCHEONS

1. Diarrhea, Bloating, and Abdominal Pain: Work-up and Treatment Algorithms
Amy S. Oxentenko, MD, FACG
Discuss a practical approach to the work-up and management of patients with diarrhea, bloating, and abdominal pain.

2. Screening and Surveillance Intervals for Colonoscopy: Navigating the Gray Zones
Aasma Shaukat, MD, MPH, FACG
Identify the appropriate screening modality and surveillance interval when guidelines are not clear.

3. Diagnostic Tools for Esophageal Disease
Miguel A. Valdovinos, MD
Discuss the use of diagnostic tools for esophageal disorders, including high resolution manometry, wireless pH and impedance-pH monitoring, and esophageal distensibility measurements.

4. Predicting the Disease Course of IBD and Tailoring Therapy
Jesús K. Yamamoto-Furusho, MD, PhD, MSc
Review the roles of endoscopic, clinical, and radiologic tools in determining the course of disease and tailoring medical therapy in IBD patients.

5. Biosimilars for IBD: Changing the Landscape
David T. Rubin, MD, FACG
Analyze the latest evidence in evolving therapies for inflammatory bowel disease and the impact on clinical care.

6. Achalasia: Diagnosis and Management
John E. Pandolfino, MD, MSCI, FACG
Discuss current diagnostic approaches and management options for achalasia.

7. Gut Microbiota Manipulation in FGID
Eamonn M. M. Quigley, MD, MACG
Review the role and importance of gut microbiota in the management of functional GI disorders.

8. Post-ERCP Pancreatitis: Who's at Risk and How to Treat
Yan G. Bakman, MD
Identify the latest evidence for pharmacological and endoscopic interventions to reduce post-ERCP pancreatitis.

9. Functional Esophageal Disorders
Ronnie Fass, MD, FACG
Discuss the diagnosis and management of functional heartburn and functional chest pain.

10. Updates in the Management of Portal Hypertension
K. Rajender Reddy, MD, FACG
Describe recent evidence and guidelines on management of portal hypertension.

11. Tips and Techniques for Removing Large Polyps
Michael B. Wallace, MD, MPH, FACG
Demonstrate tips and techniques for safe and effective removal of large colon polyps.

12. HBV Reactivation With Immunosuppressive Therapy and Management During Pregnancy
Joseph K. Lim, MD, FACG
Outline the management approach to HBV reactivation with immunosuppressive therapy, and treatment of HBV during pregnancy.

SESSION 1C: Difficult-to-Treat Esophageal Disorders
Moderators: Naïma Amrani, MD, and Nicholas J. Shaheen, MD, MPH, FACG

PPI-refractory Symptoms: Evaluation and Management
Marcelo F. Vela, MD, MSCR, FACG
Identify the optimal diagnostic approach and treatment of patients with reflux symptoms, who fail PPI therapy.

Barrett’s Esophagus: Natural History, When to Ablate, and How
Nicholas J. Shaheen, MD, MPH, FACG
Discuss the natural history, appropriate patient selection, and treatment modalities for ablation of Barrett’s esophagus.

Management of EoE: Beyond the Basics
Ikuo Hirano, MD, FACG
Explain the natural history and treatment options for eosinophilic esophagitis.

Practical Approach to Management of Extra-esophageal GERD
Michael F. Vaezi, MD, PhD, MSc(Epi), FACG
Outline the diagnostic and treatment approaches for extra-esophageal GERD.
SATURDAY SIMULTANEOUS SYMPOSIA SESSIONS

SYMPOSIUM A: Approach and Treatment of non-IBD Colitis
Moderators: Guilherme G. Macedo, MD, PhD, FACG, and Darrell S. Pardi, MD, MS, FACG

The Spectrum of Diverticular Disease: SUDD, SCAD
Brennan M.R. Spiegel, MD, MSHS, FACG
Discuss the expanding spectrum of diverticular disease and treatment options.

Microscopic Colitis: Therapy and Endpoints
Darrell S. Pardi, MD, MS, FACG
Identify the therapeutic approaches and treatment endpoints for microscopic colitis.

Treatment of Recurrent C. difficile Infection
Christina M. Surawicz, MD, MACG
Describe the latest therapeutic agents and approaches to treatment of recurrent C. difficile infection.

SYMPOSIUM B: Colon Cancer Screening: State of the Science
Moderators: Jonathan A. Leighton, MD, FACG, and Roque Sáenz, MD, FACG

Role of Non-invasive Testing in Colon Cancer Screening
Theodore R. Levin, MD, FACG
Discuss the evidence for and role of various stool-based tests used for colon cancer screening including FIT, stool DNA, and serum-based tests.

Capsule-based Endoscopy and CT Colonography for Colon Cancer Screening
Jonathan A. Leighton, MD, FACG
Describe updates in capsule endoscopy and CT colonography in colon cancer screening.

Making Sense of New and Often Contradictory Guidelines for Colon Cancer Screening
Roque Sáenz, MD, FACG
Compare and contrast key guidelines for colon cancer screening and summarize the best available approach.

SYMPOSIUM C: Updates in Liver Disease
Moderators: Kelly W. Burak, MD, FRCP, MSc (Epid), and K. Rajender Reddy, MD, FACG

Autoimmune Liver Disorders
K. Rajender Reddy, MD, FACG
Discuss a clinical approach to diagnosis and treatment of autoimmune hepatitis, PBC, and PSC.

Diagnosis and Multi-modality Management of Hepatocellular Carcinoma
Kelly W. Burak, MD, FRCP, MSc (Epid)
Explain updates in the diagnosis and multi-modality management of hepatocellular carcinoma.

Management of Alcoholic Hepatitis
Mario Reis Alventosa-Silva, MD, PhD
Identify diagnostic challenges and updates in the treatment of alcoholic hepatitis.

Sunday, October 15, 2017

SESSION 2A: Quality in Colonoscopy: What You Need to Know in 2017
Moderators: Desmond J. Leddin, MB, MSc, FRCPC, FRCPI, and Aasma Shaukat, MD, MPH, FACG

Measuring and Reporting Colonoscopy Performance
Roland Valori, MD, MB BS, FRCP, MSc (Oxon), ILTM
Describe quality measurement and reporting programs for colonoscopy performance.

Optimal Resection of Colon Polyps <10 mm
Douglas K. Rex, MD, MACG
Identify the advances and tools used in the classification and removal of colon polyps <5 mm and 5-9 mm.

Enhancing the Quality of Colonoscopy
Aasma Shaukat, MD, MPH, FACG
Evaluate the latest evidence on which quality metrics for colonoscopy are important, as well as the role of technology and other interventions to improve them.

Approach to and Management of Serrated Polyps and Serrated Polyposis Syndrome
Charles J. Kahi, MD, MSc, FACG
Discuss recognition, optimal management, and follow-up of serrated polyps and serrated polyposis syndrome.

SESSION 2B: Practical Approaches to Pancreaticobiliary Disorders
Moderators: J. Enrique Domínguez-Muñoz, MD, PhD, and Scott M. Tenner, MD, MS, MPH, JD, FACG

Approach to Cystic Lesions of the Pancreas
Anne Marie Lennon, MD, MBBCh, PhD
Apply a practical approach to diagnosis and management of cystic lesions of the pancreas.

Management of Acute Pancreatitis
Scott M. Tenner, MD, MS, MPH, JD, FACG
Evaluate recent evidence on fluid management, nutrition, and endoscopic management of acute pancreatitis.

Nutrition and Pain in Chronic Pancreatitis
J. Enrique Domínguez-Muñoz, MD, PhD
Explain the management of nutritional challenges and pain management in chronic pancreatitis.

Diagnosis and Management of Biliary Strictures
Douglas G. Adler, MD, FACG
Outline a practical approach to diagnosis and management of biliary strictures.

Autoimmune Pancreatitis
J. Shawn Mallory, MD, FACG
Identify the diagnostic criteria and treatment options for autoimmune pancreatitis.
SUNDAY LEARNING LUNCHEONS

13. Techniques for Completing the Difficult Colonoscopy
   Douglas K. Rex, MD, MACG
   Identify tips and techniques for completing difficult colonoscopy.

14. Social Media and Your Practice
    David T. Rubin, MD, FACG
    Enumerate the social media tools and their effective uses for a medical practice.

15. How to Set Up Your Practice for MACRA and MIPS Reporting
    Irving M. Pike, MD, FACG
    Discuss the optimal tracking and reporting of measures for maximizing reimbursement.

16. Updates in Management of Gastroparesis
    Brian E. Lacy, MD, PhD, FACG
    Appraise the latest treatment agents and approaches for management of gastroparesis.

17. H. pylori: Who to Treat and How
    William D. Chey, MD, FACG
    Formulate an evidence-based approach to indications and treatment options for H. pylori infection.

18. PPI Therapy: Indications, Monitoring, and When to Stop
    Kenneth R. DeVault, MD, FACG
    Discuss the latest evidence-based indications and patient selection for monitoring PPI therapy.

19. Update on Management of Ischemic Colitis
    Lawrence J. Brandt, MD, MACG
    Apply a practical approach to the diagnosis and treatment of ischemic colitis.

20. NAFLD and NASH: Diagnostic Tools and Management
    Nahum Méndez Sánchez, MD, MSc, PhD, FACG
    Outline the latest imaging and serological tests in the diagnosis of NAFLD/NASH and updates in treatment approaches.

21. Post-surgical Management of Crohn’s Disease
    Miguel D. Regueiro, MD, FACG
    Identify the optimal approach in the management of Crohn’s disease post-surgery.

22. Preventive Care for Patients With IBD
    Francis A. Farraye, MD, MSc, FACG
    Implement an evidence-based approach to preventive care in patients with inflammatory bowel disease.

23. Systematic Interventions to Improve Bowel Cleansing
    Shahnaz Sultan, MD, MHSc
    Assess various bowel preparation agents and interventions to achieve adequate bowel cleansing.

24. Approach to Abnormal Liver Function Tests
    Paul Y. Kwo, MD, FACG
    Describe the approach to abnormal liver function tests in light of recent guidelines.

SESSION 2C: Endoscopic Approaches to GI Diseases
Moderators: Abdelmunem E. Abdo, MD, and Neena S. Abraham, MD, MSc (Epid), FACG

Management of Anti-thrombotic Agents for Endoscopy
   Neena S. Abraham, MD, MSc (Epid), FACG
   Enumerate current and new anti-thrombotic agents and how to manage their use for endoscopic procedures.

Advances in the Management of Variceal Bleeding
   Abdelmunem E. Abdo, MD
   Describe updates in the endoscopic, radiologic, and surgical management of variceal bleeding.

Advances in the Management of Non-variceal Upper GI Bleeding
   John R. Saltzman, MD, FACG
   Discuss updates in the endoscopic management of non-variceal bleeding.

EMR and ESD: Tools and Techniques
   Michael B. Wallace, MD, MPH, FACG
   Demonstrate tools and techniques for effective use of EMR and ESD in resection of colonic lesions.

SUNDAY SIMULTANEOUS SYMPOSIA SESSIONS

SYMPOSIUM D: GI Cancers: A Practical Approach
Moderators: Carol A. Burke, MD, FACG, and Jaw-Town Lin, MD, PhD

Hereditary Causes of Colon Cancer
   Carol A. Burke, MD, FACG
   Outline diagnostic approaches to Lynch Syndrome, FAP, and MAP, plus recommendations for surgery and surveillance.

Pancreatic Cancer: Diagnostic Approach and Surveillance in High-risk Populations
   Ashley L. Faulx, MD, FACG
   Discuss the role of EUS in diagnosis and therapy for pancreatic cancer, and when surveillance should be advised.

Gastric Cancer: Endoscopic Management and Surveillance
   Jaw-Town Lin, MD, PhD
   Apply a practical approach to endoscopic treatment for and surveillance of gastric cancers.
SYMPOSIUM E: Viral Hepatitis
Moderators: Mario Reis Alvares-da-Silva, MD, PhD, and Paul Y. Kwo, MD, FACG

The Global Burden of Hepatitis C
Nick M. Walsh, MD, PhD, FAFPHM, FAChAM
Define the global prevalence, incidence, and stigmata of hepatitis C.

Goals of Therapy in HBV
Paul Y. Kwo, MD, FACG
Identify the goals of therapy in treatment of hepatitis B and efficacy of various therapies in achieving them.

Therapy for Hepatitis C
Jordan J. Feld, MD, MPH
Describe the updated options for hepatitis C therapy and their outcomes.

SYMPOSIUM F: Management of Obesity: Role of the Gastroenterologist
Moderators: James Toouli, MBBS, FRACS, PhD, and Mark D. Topazian, MD, FACG

Pros and Cons of Endoscopic Procedures for Obesity
Mark D. Topazian, MD, FACG
Assess the benefits and risks of endoscopic bariatric procedures.

Medical Management: Pre- and Post-bariatric Treatments
Amy E. Foxx-Orenstein, DO, MACG
Discuss the effectiveness of diet, exercise, and medications in the management of pre- and post-bariatric treatments in the obese patient.

Managing Complications of Bariatric Surgery
Reem Z. Sharaiha, MD, MSc
Describe the gastrointestinal complications of bariatric surgeries and their management.
Advancements in diagnostic measures, therapeutic options, and technology continue to evolve and impact the field of gastroenterology and hepatology. Staying abreast of the many changes in the management of gastrointestinal and liver diseases and with an aim to continue to provide top-quality patient care can be a challenge for the GI clinician. The goal three-day WCOG at ACG2017 Scientific Meeting exposes the GI expert to updates in a variety of topics, including hepatitis C, quality colonoscopy practices, IBD therapies and management, IBS treatment, PPIs, hepatology, NAFLD and NASH treatment, GERD, and more.

The Scientific Meeting program is designed primarily for physicians in gastroenterology and hepatology, as well as physician assistants, nurse practitioners, and other advanced practice healthcare professionals interested in the latest information on state-of-the-art treatment of these illnesses.

Monday, October 16, 2017

BREAKFAST A: Non-Celiac Enteropathies
Moderator: Lawrence R. Schiller, MD, MACG

What to Look for When Patients Do Not Respond to Gluten Withdrawal: Celiac Pathomimetic Diseases
Joseph A. Murray, MD, FACG
Identify other diseases that can mimic celiac disease from a clinical and histologic perspective.

Protein-losing Enteropathy: Diagnostic Approach and Treatment Options
Lawrence R. Schiller, MD, MACG
Distinguish the various diseases that can result in excessive protein loss from the GI tract and formulate a strategy to treat patients with a protein-losing enteropathy.

Enteropathies in the Developing World
Uday C. Ghoshal, MD, DNB, DM, FACG
Recognize the infectious and environmental factors that lead to enteropathies in developing countries.

BREAKFAST B: Medical-Surgical Management of Crohn's Disease
Moderator: Paulo Gustavo Kotze, MD, MsC, PhD

When Enough Is Enough: Time to Operate for Crohn's Disease
Susan Galandiuk, MD, FACC, FACS, FASCRS
Appraise refractory Crohn's disease to assess the appropriate timing of surgery and determine when medical therapy is futile.

The Postoperative Crohn's Patient: Do all Patients Need Medications?
Charles N. Bernstein, MD, FACG
Describe the role of endoscopic monitoring to assess recurrence and stratify Crohn's patients based on risk.

The Postoperative Crohn's Patient: Don't Wait for Endoscopic Recurrence, Start Treatment Early
Miguel D. Regueiro, MD, FACG
Formulate a plan for the Crohn's patient needing medical therapy post-operatively and assess the most effective treatment.
BREAKFAST C: Obesity
Moderator: James Toouli, MBBS, FRACS, PhD

Epidemiology of Obesity: A Global Perspective
James Toouli, MBBS, FRACS, PhD
Discuss why obesity is a global problem in the 21st century, its co-morbidities, and the burden of disease now and in the future.

Obesity and Disease
Amy E. Foxx-Orenstein, DO, MACG
Recognize indicators and types of cancers associated with obesity and rank these from the most common and likely to the speculative.

Surgical and Endoscopic Management of Obesity
Violeta B. Popov, MD, PhD, FACG
Identify the common bariatric operations and discuss the role of endoscopy as a primary therapy.

BREAKFAST D: Motility Testing – What Should be Incorporated into Practice?
Moderator: John E. Pandolfino, MD, MSCI, FACG

Esophageal Motility Testing
Abraham R. Khan, MD
Distinguish new and established modalities for esophageal motility testing.

Gastric Motility Testing
Braden Kuo, MD
Explain the benefits and limitations of various gastric motility tests, including fundic accommodation, gastric emptying, and manometry.

Colorectal Motility Testing
Gregory S. Sayuk, MD
Evaluate colon transit and anorectal function tests.

PRESIDENTIAL PLENARY SESSION 1
David J. Bjorkman, MD, MSPH, FACG, and Carol A. Burke, MD, FACG

1. Risk of Metachronous High-Risk Adenomas and Large (≥1 cm) Serrated Polyps in Individuals With Serrated Polyps on Index Colonoscopy: Longitudinal Data From the New Hampshire Colonoscopy Registry 2017 Category Award (Colon)
Joseph C. Anderson, MD, MHCDS, FACG1, Amitabh Srivastava, MD2, Christina Robinson, MS3, Julie Weiss, MS1, Christopher Amos, PhD1, Lynn Butterly, MD3, 1Dartmouth College Geisel School of Medicine, Hanover, NH; 2Brigham & Women’s Hospital, Boston, MA; 3Dartmouth-Hitchcock Medical Center, Lebanon, NH

2. Enhanced Recovery in Acute Pancreatitis (RAPTor): A Randomized Controlled Trial 2017 Fellows-in-Training Award (Biliary/Pancreas Category)
Elizabeth Dong, MD1, Jonathan I. Chang, MD1, Dhruv Verma, MD1, Michael Batech, DrPH2, Cecia Villarin1, Karl K. Kwok, MD1, WanSu Chen, PhD3, Bechien U. Wu, MD, MPH1; 1Kaiser Permanente Division of Research, Pasadena, CA; 2Kaiser Permanente Division of Research, Pasadena, CA

3. Functional Obstructive Gastroparesis: Effect of Laparoscopic Pyloroplasty on Symptoms, Gastric Emptying, and Gastric Myoelectrical Activity After Successful Endoscopic Pyloric Therapies
Jennifer Wellington, DO, Kenneth Koch, MD, Paula Stuart, PA-C; Wake Forest University School of Medicine, Winston-Salem, NC

4. A Prospective Validation of Deep Learning for Polyp Auto-detection during Colonoscopy 2017 International Award
Pu Wang, MD1, Xiao Xiao, PhD2, Jingjia Liu, BSc2, Liangping Li, MD1, Mengtian Tu, MS1, Jiong He, BSc2, Xiao Hu, MS1, Fei Xiong, MS1, Yi Xin, BSc2, Xiaogang Liu, MD1; 1Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan, People’s Republic of China; 2Shanghai Wision AI Co., Ltd, Shanghai, People’s Republic of China

5. Effectiveness of Endoscopic Therapy in Patients With Barrett’s Esophagus (BE) With Early Cancer Is Comparable to That of BE With High-Grade Dysplasia (HGD): Results From an International, Multi-center Consortium 2017 Category Award (Esophagus)
Rajesh Krishnamoorthi, MD1, Varun Thiagarajan, MD1, Sneekar Vennelaganti, MD2, Alessandro Repici, MD3, Vani Konda, MD4, Irving Waxman, MD4, Stefan Seewald, MD5, Matthew Stier, MD6, Rehan Haidry, MD7, Daniel Buckles, MD8, Neil Gupta, MD9, Ajay Bansal, MD10, Sharad Mathur, MD8, Mojtaba Olyaei, MD10, Michael Bourke, MD11, Gary Fald, MD12, Prateek Sharma, MD12, Andrew S. Ross, MD13; 1Virginia Mason Medical Center, Seattle, WA; 2Kansans City VA Medical Center, Kansas City, MO; 3Instituto Clinico Humanitas, Milan, Italy; 4University of Chicago, Chicago, IL; 5Hirslanden, Zurich, Switzerland; 6University of Chicago Medical Center, Chicago, IL; 7University College London Hospital, London, United Kingdom; 8University of Kansas, Kansas City, KS; 9Loyola University, Maywood, IL; 10University of Kansas Medical Center, Kansas City, KS; 11University of Sydney, Westmead, Australia; 12Hospital of the University of Pennsylvania, Philadelphia, PA; 13Digestive Diseases Institute, Virginia Mason Clinic, Seattle, WA

PRESIDENTIAL PLENARY SESSION 2
Moderators: Irving M. Pike, MD, FACG, and Cihan Yurdaydin, MD

6. In vivo Detection of Colonic Mucosa Microinflammation by Confocal Laser Endomicroscopy Probe (p-CLE) in Patients With Irritable Bowel Syndrome 2017 Category Award (Functional Bowel Disease)
Carlos Robles-Medranda, MD, Manuel Valero, MD, Miguel Soria-Alcivar, MD, Miguel Puga-Tejada, MD, MSc, Jesenia Ospina-Arboleda, MD, MSc, Haydee Alvarado-Escobar, MD, Guillermo Munoz-Jurado, MD, Roberto Oleas, Hannah Pitanga-Lukashok, MD; Ecuadorian Institute of Digestive Diseases, Guayaquil, Guayas, Ecuador

Medical Center, Los Angeles, CA; 2Kaiser Permanente Division of Research, Pasadena, CA; 3Kaiser Permanente Division of Research, Pasadena, CA
7. Signature of Circulating microRNA (miR) Detected by NextSeq Differentiates Non-alcoholic Fatty Liver Disease (NAFLD) Patients With Higher Percentage Hepatic Collagen: A Potential Role for a Prognostic Biomarker

Zobair M. Younossi1, Azza Karrar, PhD1, Kira Tokarz, MS2, Anatoly Ulyanov, PhD2, Maria Stepanova, PhD3, Zahra Younoszai, BS1, Thomas Jeffers, BS1, Sean C. Felix, BS1, Daisong Tan, MD2, Ahmad Moin, MD2, Ramaswamy Iyer, MD2, John Deeken, MD2, Zachary Goodman, MD, PhD4; 1Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA; 2Inova Fairfax Hospital, Falls Church, VA; 3Center for Outcomes Research in Liver Disease, Washington, DC; 4Center For Liver Disease, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA

8. A National Survey of Burnout in Gastroenterologists

Carol A. Burke, MD, FACG1, Christina M. Surawicz, MD, MACG2, Amy S. Oxentenko, MD, FACP3, Rocio Lopez, MS, MPH1, Shashank Sarvepalli, MD1, Joseph C. Anderson, MD, MHCD1, FACP4, Kenneth R. DeVault, MD, FACP5, Costas H. Kefalas, MD, MMM1, FACG6, Daniel J. Pambianco, MD, FACP7, Sarah Richman, BA8, Harry E. Sarles, MD, FACP9, Anna-Louise B. Oliphant, MPP8, Joseph C. Anderson, MD, MHCDS, FACG10; 1Cleveland Clinic Foundation, Cleveland, OH; 2University of Washington, Seattle, WA; 3Mayo Clinic, Rochester, MN; 4Dartmouth College Geisel School of Medicine, Hanover, NH; 5Mayo Clinic, Jacksonville, FL; 6Akron Digestive Disease Consultants, Inc., Akron, OH; 7Charleston Gastroenterology Associates, Charleston, SC; 8American College of Gastroenterology, Bethesda, MD; 9Digestive Health Associates of Texas, Rockwall, TX; 10Yale University School of Medicine, New Haven, CT


Siew C. Ng, MBBS1, PhD1, Hai Yun Shi, MD1, Nima Hamidi, MD2, Fox Underwood, MSc3, Whitney Tang, MD2, Eric Benchimol, MD, PhD4, Remo Panaccione, MD, FRCPC5, Subrata Ghosh, MD6, Justin Wu, MD2, Francis Chan, MD2, Joseph Sung, MD2, Gilaad Kaplan, MD, MPH 3; 1Chinese University of Hong Kong, Shatin, Hong Kong; 2Chinese University of Hong Kong, Hong Kong; 3University of Calgary, Calgary, AB, Canada; 4Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada; 5University of Calgary, Department of Medicine, Calgary, AB, Canada; 6Institute of Translational Medicine, Birmingham, United Kingdom

10. Risk of Alcohol Abuse Is Increased After Bariatric Surgery: A Systematic Review and Meta-Analysis

Praneet Wander, MD1, Daniel Castaneda, MD2, Joanna Dognin, PsyD3, Christopher C. Thompson, MD, MHEST, FACG4, Violeta Popov, MD, PhD, FACP3; 1Mount Sinai St. Luke’s and Mount Sinai Roosevelt, New York, NY; 2Mount Sinai St. Luke’s and Mount Sinai West Hospitals, New York, NY; 3New York University School of Medicine, New York, NY; 4B Brigham & Women’s Hospital, Boston, MA

SIMULTANEOUS SYMPOSIA SESSIONS

SIMULTANEOUS SYMPOSIUM 1A: Hepatocellular Carcinoma
Moderators: David E. Bernstein, MD, FACG, and Kelly W. Burak, MD, FRCP, MSc (Epid)

Worldwide Epidemiology of Hepatocellular Carcinoma (HCC)
Hashem B. El-Serag, MD, MPH
Describe current and evolving global epidemiology, natural history, clinical course, and risk factors for HCC.

Diagnosis and Screening of Hepatocellular Carcinoma (HCC)
Amit Singal, MD, MS
Explain current guidelines on the screening, diagnosis, and staging of HCC.

Treatment of Hepatocellular Carcinoma (HCC)
Mario Reis Alves-da-Silva, MD, PhD
Discuss current and evolving multidisciplinary treatment paradigms for HCC, including medical management, interventional radiology, surgery, and radiation oncology.

SIMULTANEOUS SYMPOSIUM 1B: Endosurgery in the Upper GI Tract
Moderators: Vitor Arantes, MD, MSc, PhD, and Qiang Cai, MD, PhD, FACG

Endoscopic Myotomy for Achalasia and Beyond
Peter V. Dragano, MD, FACP
Define the role of POEM versus surgical approaches for achalasia and newer indications.

Extreme and Unconventional Esophageal Endoscopic Solutions: Stents, Sutures, and Clips
Vivek Kaul, MD, FACG
Describe endoscopic approaches to managing complex esophageal cases and complications.

Advances in the Third Lumen in the Upper GI Tract: ESD, STER, Full-thickness Resection
Haruhiro Inoue, MD, PhD
Describe novel approaches for removing upper GI lesions.

SIMULTANEOUS SYMPOSIUM 1C: Colorectal Cancer Screening: Global Approaches
Moderators: Carmelo Scarpignato, MD, DSc, FRCP, FACG, and Aasma Shaukat, MD, MPH, FACG

CRC Screening: Global Overview
Linda Rabeneck, MD, MPH, MACG
Summarize the spectrum of global strategies for colon cancer screening.

CRC Screening in Regions With Limited Resources
Roque Sáenz, MD, FACG
Propose strategies for colon cancer screening in areas with limited resources.
Non-colonoscopy Colon Cancer Screening Tests: State-of-the-Art 2017
Mark B. Pochapin, MD, FACG
Discuss the best uses for non-colonoscopic colon cancer screening tests, specifically FIT and stool DNA testing.

SIMULTANEOUS SYMPOSIUM 1D: H. pylori — Diagnostic and Therapeutic Challenges Across the Globe
Moderators: William D. Chey, MD, FACG, and Henry Cohen, MD, FACP

Epidemiology of H. pylori Infection Around the World
Henry Cohen, MD, FACP
Discuss the epidemiology and differentiate the risks of H. pylori infection throughout the world.

Diagnostic Challenges of H. pylori Infection
William D. Chey, MD, FACP
Compare the characteristics and accuracy of various tests for H. pylori infection.

Treatment and Confirmation of H. pylori Eradication
Steven F. Moss, MD, FACP
Discuss treatment regimens and rationale for confirming eradication in select populations with H. pylori.

WGO’S HENRY L. BOCKUS LECTURESHP
Does Portal Pressure Guide Management of Portal Hypertension and its Complications?
Shiv Kumar Sarin, MD, DM
Describe invasive and noninvasive measurement of portal pressure, rational approach to managing complications of portal hypertension, and new vistas beyond beta-blocker therapy.

THE AMERICAN JOURNAL OF GASTROENTEROLOGY
LECTURE
Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care
Corey A. Siegel, MD, MS
Describe how IBD patient care can be improved by optimizing and individualizing the treatments currently available.

SIMULTANEOUS PLENARY SESSIONS

SESSION 1A: Liver
Moderators: Kelly W. Burak, MD, FRCP, MSc (Epid), and Tram T. Tran, MD, FACP

11. Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir to Treat HCV Genotype 1-6 Infection in Patients Without Cirrhosis Including HIV Co-Infection
David E. Bernstein, MD, FACP,1 Graham Foster, MD, PhD,2 Douglas Dylla, PhD,3 Stefan Mauss, MD,4 David Nelson, MD,5 Tarik Asselah, MD,6 Steven Flamm, MD,7 Curtis Cooper, MD,8 Ran Liu, PhD,9 Rolando Viani, MD,3 Stanley Wang, MD, PhD,10 Federico Mensa, MD,3 Mark Sulkowski, MD,9; 1Hofstra Northwell School of Medicine, Manhasset, NY; 2Queen Mary University of London, London, United Kingdom; 3Abbvie, Inc., North Chicago, IL; 4Zentrum für HIV und Hepatogastroenterologie, Düsseldorf, Germany; 5University of Florida, Gainesville, FL; 6Hopital Beaujon, Clichy, France; 7Northwestern University Feinberg School of Medicine, Chicago, IL; 8University of Ottawa, Ottawa, ON, Canada; 9Johns Hopkins University School of Medicine, Baltimore, MD

12. Degree of Estimated Fibrosis in Asymptomatic Subjects With Non-Alcoholic Fatty Liver Disease Correlates With Higher Cardiovascular Risk
Maria Cristina Moreno del Castillo, MD, Alain Sanchez Rodriguez, MD, Javier Jose Hernandez Buen Abad, MD, Jose Ramon Mena Ramirez, MD, Ricardo Garcia-Buen-Abad, MD, Natalie Atkinson, MD, Maria Emilia Mendizabal Rodriguez, MD, Jonathan Salazar Segovia, MD, Ignacio Garcia Juarez, MD; American British Cowdray, Medical Center, Mexico City, Distrito Federal, Mexico

13. Validity of Non-Invasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type 2 Diabetes With Suspected Non-Alcoholic Fatty Liver Disease
2017 ACG Governors Award for Excellence in Clinical Research
Amandeep Singh, MD1, Rocio Lopez, MS, MPH 1, Eric Lawitz, MD2, Fred Poordad, MD, Naim Alkhouri, MD; 1Cleveland Clinic Foundation, Cleveland, OH; 2Texas Liver Institute, San Antonio, TX

SESSION 1B: IBD
Moderators: Stephen B. Hanauer, MD, FACG, and Jimmy K. Limdi, MD, FACP

14. Safety and Efficacy of Long-term Treatment With Ozanimod: An Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis — TOUCHSTONE Extension 2-Year Follow-up
William J. Sandborn, MD1, Brian G. Feagan, MD, FACP2, Geert D’Haens, MD, PhD3, Stephen Hanauer, MD4, Douglas C. Wolf, MD, Séréine Vermeire, MD, PhD, Subrata Ghosh, MD,7 Ciayn Li, PhD8, Darryl Penenberg, PhD8, AnnKatrin Petersen, MD8, Richard Aranda, MD8, Allan Olson, MD, MBA8; 1University of California, La Jolla, CA; 2Robarts Research Institute, Western University, London, ON, Canada; 3Academic Medical Center, Amsterdam, Noord-Holland, Netherlands; 4Feinberg School of Medicine, Northwestern University, Evanston, IL; 5Atlanta Gastroenterology Associates, Atlanta, GA; 6University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium; 7University of Calgary, Calgary, AB, Canada; 8Receptos, a wholly owned subsidiary of Celgene, San Diego, CA

15. Paradoxical Trends in Hospitalization Rates for the Inflammatory Bowel Diseases Between the Western World and Newly Industrialized Countries: A Study of the Organization for Economic Cooperation and Development (OECD)
James A. King, BA1, Fox Underwood, MSc1, Nicola Panaccione1, Josh Quan1, Paulo Kotze, MD, PhD 2, Siew C. Ng, MBBS, PhD3, Subrata Ghosh, MD4, Peter
SESSION 1C: Endoscopy
Moderators: Serhat Bor, MD, and Delbert L. Chumley, MD, FACG

17. Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients on Chronic Opioids: A Randomized Controlled Trial
2017 Category Award (General Endoscopy)
Salman Nusrat, MD, Mohammad F. Madhoun, MD, MSCI, Muhammad H. Bashir, MD, William M. Tierney, MD; University of Oklahoma Health Sciences Center, Oklahoma City, OK

18. Is CO2 Better Than Air for Insufflation During Colonoscopy In Reducing Post-Procedural Pain? A Meta-Analysis of Randomized Controlled Trials
Ajai S. Rajabalan, MD1, Kamaldeep Singh, MD2, Diwas Shahi1, Sunil D. Paudel, MD1, Venkata Suresh Patthipati, MD1, Thara Vidyasagaran, MD3, Samir Patel, MD, MPH4, Milan Dodig, MD5; 1University of Texas Southwestern Medical Center, Dallas, TX; 2Cleveland Clinic, Cleveland, OH; 3University of Cincinnati College of Medicine, Cincinnati, OH, USA; 4Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 5University of North Carolina School of Medicine, Chapel Hill, NC, USA; 6Mount Sinai School of Medicine, New York, NY, USA; 7University of Utah School of Medicine and Huntsman Cancer Institute, Salt Lake City, UT, USA; 8University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; 9Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA; 10University of Arizona, Tucson, AZ, USA; 11University of Iowa Hospitals and Clinics, Iowa City, IA, USA; 12Sanofi, Bridgewater, NJ, USA; 13Sanofi, Chilly-Mazarin, France

SESSION 1D: Late-Breaking Abstracts
Moderators: Necati Ormeci, MD, and Daniel J. Pambianco, MD, FACG

20. Dupilumab Efficacy and Safety in Adult Patients With Active Eosinophilic Esophagitis: A Randomized Double-Blind Placebo-Controlled Phase 2 Trial
Ikuko Hirano1*, Evan S. Dellon2*, Jennifer D. Hamilton3, Margaret H. Collins4, Kathryn Peterson5, Mirna Chehade6, Alain M. Schoepfer7, Ekaterina Safroeneva8, Marc E. Rothenberg9, Gary W. Falk10, Yehudith Assouline-Dayan11, Zhizhi Qing3, Brian N. Swanson12, Gianluca Pirozzi12, Leda Mannent13, Neil M.H. Graham3, Bolanle Akinlade3, Allen Radin3 (*Co-first authors); 1Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2University of North Carolina School of Medicine, Chapel Hill, NC, USA; 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 4Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, USA; 5University of Utah School of Medicine, Salt Lake City, UT, USA; 6Mount Sinai Hospital for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 7Centre Hospitalier Universitaire Vaudois et Université de Lausanne, Lausanne, Switzerland; 8Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 9Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 10University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; 11University of Iowa Hospitals and Clinics, Iowa City, IA, USA; 12Sanofi, Bridgewater, NJ, USA; 13Sanofi, Chilly-Mazarin, France

21. Minimally Invasive Surgery versus Endoscopy Randomized (MISER) Trial for Necrotizing Pancreatitis
Ji Young Bang, MD, MPH, Pablo Arnoletti, MD, Muhammad Hasan, MD, Udayakumar Naveenathan, MD, Bryce Sutton, PhD, Robert H. Hawes, MD, FACG, Shyam Varadarajulu, MD; Center for Interventional Endoscopy, Florida Hospital, Orlando, FL

22. A Prospective RCT Comparing Proximal ADR (Primary Outcome) Using Combined Chromoendoscopy With Water Exchange (CWE) versus Water Exchange (WE) versus Air Insufflation (AI) in Screening Colonoscopy
J. Leung, MD, MACG1,2, A. Yen, MD, FACG1, C. Opada, RN1, A. Melnik, BSc1, C. Feller, RDN, CCRP1, M. Wilson, PhD3, F. Leung, MD, FACG4; 1Sacramento VA Medical Center, Sacramento, CA; 2UC Davis Medical Center, Sacramento, CA; 3Clinical and Translational Science Center, UC Davis, Sacramento, CA; 4Sepulveda Ambulatory Care Center, VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, Los Angeles, CA
SIMULTANEOUS SYMPOSIA SESSIONS

SIMULTANEOUS SYMPOSIUM 2A: Gluten-related Disorders
Moderators: Julio C. Bai, MD, and Eamonn M. M. Quigley, MD, MACG

A Global Update on Celiac Disease and its Complications
Carolina Ciacci, MD
Recognize the clinical spectrum of gluten-related disorders and their complications worldwide.

Current and Emerging Management for Celiac Disease
Peter H. R. Green, MD, FACG
Identify the current management of celiac disease, and the emerging therapies on the horizon.

Non-celiac Gluten Sensitivity
Julio C. Bai, MD
Summarize the clinical features and management of non-celiac gluten sensitivity.

SIMULTANEOUS SYMPOSIUM 2B: Advances in Hepatitis C Therapy: 2017 Update
Moderators: Joseph K. Lim, MD, FACG, and Guilherme G. Macedo, MD, PhD, FACG

Global Eradication of HCV: Can It Be Achieved?
Douglas R. LaBrecque, MD
Discuss global epidemiology of chronic hepatitis C infection and current challenges in addressing delivery of oral direct-acting antiviral (DAA) regimens in resource-limited settings.

Current Treatment of HCV
Paul Y. Kwo, MD, FACG
Describe the current evidence base and guidelines for HCV therapy with available direct-acting antiviral (DAA) regimens.

Treatment of Special Populations With HCV
Norah A. Terrault, MD, MPH, FACG
Identify current strategies for management of special populations with HCV, including patients who have failed direct-acting antiviral (DAA) regimens, HCV-HIV co-infection, end-stage renal disease, and decompensated cirrhosis.

SIMULTANEOUS SYMPOSIUM 2C: Global Perspectives in IBD: Evolution and Management
Moderators: Charles N. Bernstein, MD, FACG, and Stephen B. Hanauer, MD, FACG

IBD Emerging Across the World: Epidemiology and Differential Diagnosis
Jesús K. Yamamoto-Furusho, MD, PhD, MSc
State the current epidemiology of IBD worldwide and discuss differential diagnosis worldwide, particularly with regard to tuberculosis.

Optimizing the Efficacy of Current IBD Therapies: Making the Most of What You Have
Lisa B. Malter, MD, FACG
Design an algorithm for selecting and monitoring therapy for mild-to-moderate IBD.

IBD in the Era of International Travel: Vaccines, Vectors, and Viruses
Gerhard Rogler, MD, PhD
Discuss the IBD-related risks travelers face globally and techniques to minimize risk.

SIMULTANEOUS SYMPOSIUM 2D: Live from Orlando!
The 5th Annual Endoscopy Video Forum
Moderator: Seth A. Gross, MD, FACG

The Video Forum Symposium features the best video presentations submitted by colleagues from across the U.S. and around the world. Submitted during ACG’s Call for Abstracts and peer-reviewed and selected for presentation, the cases feature interesting endoscopic findings and techniques encountered in daily clinical practice.

V1. EUS-Guided Continuous Catheter Thrombolysis of Portal Venous System
Malay Sharma, MBBS, MD, DM, Piyush Somani, MBBS, MD, DM, Saurabh Jindal, MBBS, MD, DM; Jaswant Rai Specialty Hospital, Meerut, Uttar Pradesh, India

V2. Underwater Complex Colonic ESD With Retraction and Specimen Retrieval: First Human Experience Using a Double Balloon Device
Sam Sharma, MD1, Kota Momose, MD1, Krishna Gurram, MD2, Stavros Stavropoulos, MD2; 1New York-Presbyterian/Weill Cornell Medical Center, New York, NY; 2Winthrop University Hospital, New York, NY

V3. Transtracheal Cyanoacrylate Glue Injection for the Management of Malignant Tracheoesophageal Fistula
Piyush Somani, MBBS, MD, DM; Malay Sharma, MBBS, MD, DM, Saurabh Jindal, MBBS, MD, DM; Jaswant Rai Specialty Hospital, Meerut, Uttar Pradesh, India

V4. Office Management of Acute Thrombosed Hemorrhoids in a Pregnant Patient
Waqar Qureshi, MD, FACG, FRCP; Baylor College of Medicine, Houston, TX

V5. Double Tunnel Endoscopic Submucosal Tunnel Dissection for Rectal Circumferential Laterally Spreading Tumor
Wei Gong, MD, PhD1, Silin Huang, MD2; 1Nanfang Hospital of Southern Medical University, Shenzhen Hospital of Southern Medical University, Guangzhou, Guangdong, People’s Republic of China; 2Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, People’s Republic of China

V6. Endoluminal Vacuum for Spontaneous Esophageal Perforation
Jennifer Liu-Burdowski, MD, Anoop Appannagari, MD2, Juan Carlos Bucobo, MD1; 1Stony Brook University School of Medicine, Stony Brook, NY; 2Stony Brook University Hospital, Stony Brook, NY
**V7. Versatility of Transnasal Endoscope**  
Saikiran Raghavapuram, MD1, Abhilash Perisetti, MD, FACP2, Michael Johnson, MD3, Rayburn Rego, MD3;  
1University of Arkansas for Medical Sciences, Little Rock, AR; 2Texas Tech University Health Sciences Center, Lubbock, TX; 3Central Arkansas Veterans Health Care System, Little Rock, AR

**V8. Endoscopic Placement of Sengstaken-Blakemore Tube for Bleeding Esophageal Varices**  
Michael McCabe, MD1, Nicolas Intagliata, MD1, Stephen Caldwell, MD2;  
1University of Virginia Digestive Health Center, Charlottesville, VA; 2University of Virginia Medical Center, Charlottesville, VA

**V9. EUS-Guided Coil Embolization and Thrombin Injection of Bleeding Gastroduodenal Artery Pseudoaneurysm**  
Piyush Somani, MBBS, MD, DM, Malay Sharma, MBBS, MD, DM, Saurabh Jindal, MBBS, MD, DM; Jaswant Rai Specialty Hospital, Meerut, Uttar Pradesh, India

---

**Tuesday, October 17, 2017**

**BREAKFAST E: Small Bowel Bleeding**  
*Moderator: Carolina Olano, MD, MSc (Ed)*

**Evaluation of the Patient With Suspected Small Bowel Bleeding**  
*Carolina Olano, MD, MSc (Ed)*

Explain the step-wise diagnostic approach to the patient with suspected small bowel bleeding.

**Management of Recurrent Small Bowel Bleeding: Endoscopic, Medical, or Surgical Therapy?**  
*Cristiano Spada, MD, PhD*

Describe management strategies for the patient with recurrent small bowel bleeding that has not been identified or controlled with initial testing.

**Therapeutic Efficacy of Radiographic Modalities to Control Small Bowel Bleeding**  
*Sailendra G. Naidu, MD*

Identify the role of radiographic intervention in patients with small bowel bleeding, and the advantages and limitations of various diagnostic and therapeutic tests.

**BREAKFAST F: All Things Pancreatitis**  
*Moderator: Timothy B. Gardner, MD, MS, FACP*

**Pharmacologic and Endoscopic Strategies to Prevent Post-ERCP Pancreatitis**  
*Douglas G. Adler, MD, FACP*

Describe the pharmacologic and endoscopic interventions used to minimize post-ERCP pancreatitis.

**Diagnosis of Early Chronic Pancreatitis**  
*Timothy B. Gardner, MD, MS, FACP*

Explain the criteria and tests used for diagnosing early chronic pancreatitis.

---

**BREAKFAST G: Controversies in Barrett’s Esophagus**  
*Moderator: Nicholas J. Shaheen, MD, MPH, FACP*

**Barrett’s Esophagus: Screening and Surveillance**  
*Prateek Sharma, MD, FACP*

Discuss current guidelines for screening and surveillance of Barrett’s esophagus.

**Cut, Burn, Freeze: What Is the Best Weapon for Dysplastic BE?**  
*Nicholas J. Shaheen, MD, MPH, FACP*

Define how to choose among the current treatment options for ablation of Barrett’s esophagus.

**Should all Low-grade Dysplasia Get Ablative Therapy?**  
*Prasad G. Iyer, MD, MS, FACP*

Discuss whether low-grade dysplasia should be treated aggressively or observed aggressively.

**BREAKFAST H: Diverticular Disease: New Data and New Guidelines**  
*Moderator: Lisa L. Strate, MD, MPH, FACP*

**SUDD and SCAD: Are They a ‘Thing’? Can We Treat Them?**  
*Carmelo Scarpignato, MD, DSc, FRCP, FACP*

Analyze the data in support of Symptomatic Uncomplicated Diverticular Disease (SUDD) and Segmental Colitis Associated with Diverticulosis (SCAD) as distinct clinical entities and review potential treatment options for both.

**Treatment and Prevention of Acute and Recurrent Diverticulitis**  
*Neil H. Stollman, MD, FACP*

Appraise medical treatment of acute diverticulitis and potential preventive measures for recurrent diverticular disease.

**Diverticular (and Other) Lower GI Bleeding: New Guidelines**  
*Lisa L. Strate, MD, MPH, FACP*

Summarize current best practices for medical and endoscopic treatment of lower GI bleeding.

**BREAKFAST I: Advances in IBD Diagnosis and Management: The Future Looks Like This**  
*Moderator: Fernando S. Velayos, MD, MPH*

**The Latest and Greatest in Small Bowel Imaging: X-rays, Ultrasounds, Capsule Endoscopy, and MRI**  
*Shabanana F. Pasha, MD*

Compare the current methods of small bowel imaging in IBD and determine when to choose each modality.
Endoscopic Management of Complications of Crohn’s Disease
Bo Shen, MD, FACG
Demonstrate methods to use endoscopy for strictures, including dilation and needle knife.

Across the Globe: A Comparison of Practices for Surveillance and Management of Dysplasia in IBD
Fernando S. Velayos, MD, MPH
Discuss the appropriate management of IBD dysplasia surveillance, and describe how it differs globally and whether there is an international consensus.

BREAKFAST J: Practice Optimization: Making the Most of a Good Thing!
Moderator: Henry Cohen, MD, FACG

Expanding the Healthcare Team: The Use of Non-physician Providers
Colleen M. Schmitt, MD, MHS, FACG
Identify the various strategies to incorporate non-physician providers into your clinical and endoscopic practice to facilitate your day-to-day activities.

Providing Access for Your Patients: Face-to-Face versus Remote Modalities
Henry Cohen, MD, FACG
Describe differing mechanisms that can aid in patient-physician communication using non-physician providers and novel strategies.

Setting up a Disease Management Program
Costas H. Kefalas, MD, MMM, FACG
Illustrate ways that a disease management program can be incorporated into practice to optimize the care of patients with chronic disease.

BREAKFAST K: Hot Topics in Liver Disease
Moderator: Stanley M. Cohen, MD, FACG

Current and Emerging Treatment Options for NASH: What You Can Do Now and What Is Coming in the Near Future
Arun J. Sanyal, MD
Assess current guidelines for the diagnosis and staging of non-alcoholic steatohepatitis (NASH) and describe evolving and future strategies for medical, endoscopic, and surgical management.

Management of Alcoholic Hepatitis
Patrick G. Northup, MD
Discuss current strategies for the diagnosis and staging of severe acute alcoholic hepatitis, and review guidelines for medical and nutritional therapy.

Clinical Presentation and Management of DILI
Guilherme G. Macedo, MD, PhD, FACG
Describe the epidemiology of drug induced liver injury (DILI), and review current guidelines on its diagnosis, clinical presentation, and management.

BREAKFAST L: Management of Early Gastric Cancer and its Precursors
Moderator: Douglas R. Morgan, MD, MPH, FACG

Surveillance and Screening Upper Endoscopy: What Can We Learn From the East?
Hiroyuki Aihara, MD, PhD, FACG
Summarize the Asian approach to screening and surveillance for gastric cancer.

Endoscopic Diagnosis and Management of Gastric Intestinal Metaplasia
Douglas R. Morgan, MD, MPH, FACG
Outline a management strategy for patients with gastric intestinal metaplasia.

Management of Early Gastric Cancer: When and How
Jaw-Town Lin, MD, PhD
Differentiate endoscopic and surgical options for treatment of early gastric cancer.

SIMULTANEOUS PLENARY SESSIONS
SESSION 2A: Pancreatico-Biliary / GI Bleeding
Moderators: Duvvur Nageshwar Reddy, MD, DM, DSc, FAMS, FRCP, FACG, MWGO, and John R. Saltzman, MD, FACG

23. Increasing Incidence of Malignant IPMN (m-IPMN) and Poorer Survival Among African Americans 2017 Category Award (Biliary/Pancreas)
Felix H. Lui, MD1, Richard Shaw, PhD2, Lauren B. Gerson, MD, MA2; 1University of California Irvine Medical Center, Anaheim, CA; 2California Pacific Medical Center, San Francisco, CA

24. Volatile Organic Compound Biomarker Signature in Bile to Distinguish Pancreatic Cancer From Chronic Pancreatitis: A Single Blinded Study 2017 ACG Auxiliary Award (Member)
Udayakumar Navaneethan, MD, FACG1, Chad Spencer, MD2, David Grove, PhD3, Xiang Zhu, MS2, Mansour Parsi, MD4, John Vargo, MD4, Muhammad Khalid Hasan, MD2, Robert Hawes, MD, FACG2, Ji Young Bang, MD, MPH2, Shyam Varadarajulu, MD2, Raed Dweik, MD4; 1Florida Hospital, University of Central Florida College of Medicine, Orlando, FL; 2Center for Interventional Endoscopy, Florida Hospital, Orlando, FL; 3Cleveland Clinic Lerner Research Institute, Cleveland, OH; 4Cleveland Clinic Foundation, Cleveland, OH

25. Initial Imaging in Patients With Acute Pancreatitis: Impact of Quality Improvement
Stephen Steele, MD1, Heathen L. Branstetter, MD1, Jimmy Shah, MHA1, Priyanka Acharya, MSc, MPH1, Nathaniel Avila, MD1, Huda Khan, MD1, Rathen Reddy, MD1, Matthew Muller, MD2, Prashant Kedia, MD1, Paul Tarnasky, MD1; 1Methodist Dallas Medical Center, Dallas, TX; 2Methodist Dallas Medical Center, Fort Worth, TX
26. Utility of HIDA Scan in Predicting Outcome of Cholecystectomy in Patients With Chronic Acute Gallbladder Disease? A Systematic Review
Nazar Hafiz, MD1, Seth D. Crockett, MD, MPH2; 1Louisiana State University Health Sciences Center, Shreveport, LA; 2University of North Carolina School of Medicine, Chapel Hill, NC

27. Periprocedural Fluid Type and Volume Reduce the Risk of Post-ERCP Pancreatitis in High-Risk Patients: A Secondary Analysis of a Randomized Controlled Trial
2017 ACG Governors Award for Excellence in Clinical Research
Venkata Akshintala, MD, Ayesha Kamal, MD2, Rupiyoti Talukdar, MD, DJ, Rajesh Goud, BSc3, Mouen Khashab, MD, MD1, Vikesh K. Singh, MD1; 1Johns Hopkins University Hospital, Baltimore, MD; 2Johns Hopkins University School of Medicine, Baltimore, MD; 3Asian Institute of Gastroenterology, Hyderabad, Telangana, India

28. TC-325 (HEMOSPRAY™) versus Standard of Care in Managing Malignant Gastrointestinal Bleeding: A Pilot Randomized Clinical Trial
2017 Category Award (GI Bleeding)
Yen-I Chen, MD, MD1, Yidan Lu, MD, MD1, Jonathan Wyse, MD2, Waqqs Afif, MD1, Talat Bessissow, MD1, Genevieve White1, Myriam Martel, BSc1, Alan Barkun, MD, CM, MSc (Clinical Epi.), FACS1, FACP1, FRCPC1, 1McGill University Health Centre, Montreal, PQ, Canada; 2Jewish General Hospital, Montreal, PQ, Canada

29. "Weekend Effect" in Patients With Upper Gastrointestinal Hemorrhage: A Systematic Review and Meta-Analysis
Ashutosh Gupta, MD1, Rajender Agarwal, MD1, MPH2, Ashwin Ananthakrishnan, MD3; 1Medical Center Hospital, Odessa, TX; 2North Mississippi Medical Center, Tupelo, MS; 3Massachusetts General Hospital, Boston, MA

30. Comparison of Glasgow-Blatchford Score and Modified Glasgow-Blatchford Score Performance in Patients With Acute Non-variceal Upper and Lower Gastrointestinal Bleeding
2017 Fellows-in-Training Award (GI Bleeding Category)
Jian Guan, MD, PhD, Evgeny Idrisov, MD, Sameen Khalid, MD, Mohammad Sharbatji, MD, Xiaoping He, MD, PhD, Christopher Armstrong, MD, Christian Colon Ripoll, MD, Alvina Munaf, MD, Ahmad Ali, MD, Fnu Asad ur Rahman, MD, MBBS, Khalid Abusaada, MD; Florida Hospital, Orlando, FL

31. A Comparison of Azithromycin to Erythromycin Infusions in Improving Visualization of Endoscopy for Upper Gastrointestinal Bleeding
Danny Issa, MD1, Sanjeev Solomon, MD2, Brian Di Pace, MPH2, Jonathan C. Hillyard, DO3, Christopher Young, MD2, George Smallfield, MD3; 1Virginia Commonwealth University School of Medicine, Richmond, VA; 2Virginia Commonwealth University, Richmond, VA; 3Virginia Commonwealth University Health System, Richmond, VA

32. Rapid Relief of Functional Dyspepsia Symptoms With a Novel Formulation of Caraway Oil and L-menthol: Outcomes From a Self-reported Patient Outcomes Study
William D. Chey, MD, FACG1, Brian E. Lacy, MD, PhD, FACG2, Brooks D. Cash, MD, AGAF, FACG, FASGE3, Michael Epstein, MD, AGAF, FACG 4, Syed M. Shah, PhD5; 1Michigan Medicine, Ann Arbor, MI; 2Dartmouth-Hitchcock Medical Center, Lebanon, NH; 3University of South Alabama, Mobile, AL; 4Digestive Disorders Associates, Annapolis, MD; 5IM HealthScience, Boca Raton, FL

33. Inpatient Mortality After PEG versus Other Techniques of Gastrostomy Tube Placement
2017 Fellows-in-Training Award (General Endoscopy Category)
Akeem O. Adebogun, MD, MPH, Marco A. Paez, MD, Gbeminiyi Samuel, MD, MPH, Musa Abdullahi, MD, Adeyinka Lajyemo, MD, MPH; Howard University Hospital, Washington, DC

34. A Randomized, Placebo-Controlled Trial of the Effects of Aprepitant, an NK1 Receptor Antagonist, on Gastric Motor Functions and Satiation in Healthy Volunteers
Deepthi A. Jacob, BSc, MD, Irene Busciglio, BS, Duane Burton, MHA, Houssam Halawi, MD, Ibronoke Oduyebo, MD, Deborah Rhoten, Michael Ryks, William Scott Harmsen, MS, Michael Camilleri, MD, FACG; Mayo Clinic, Rochester, MN

35. A Lower Hemoglobin Concentration Cutoff for Abnormal Fecal Immunochemical Testing Substantially Increases Colorectal Cancer and Advanced Neoplasia Detection in a System Level Mailed Outreach Program
Emily Berry, MSPH1, Stacie Miller, RN, MSN, MPH1, Mark Koch, MD2, Keith Argenbright, MD, MM3, Bijal A. Balasubramanian, MBBS, PhD4, Samir Gupta, MD, MScS5; 1Moncrief Cancer Institute, Fort Worth, TX; 2John Peter Smith Health Network, Fort Worth, TX; 3UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX; 4University of Texas Health Science Center at Houston, Dallas, TX; 5VA San Diego, La Jolla, CA

36. Clinicopathologic Features of Young Onset Colorectal Cancer Patients: Results From a Large Cohort at a Single Cancer Center
Leslie Park, MD1, Kelli O’Connell, MSPH1, Keri Herzog, MD2, Andrea Cercek, MD1, Zsofia Stadler, MD1, Jinrui Shia, MD1, Moshe Shik, MD1, Arnold Markowitz, MD1, Jose G. Guillem, MD, MPH1, Julio Garcia-Aguilar, MD, PhD1, Mark Schattner, MD, FASGE, AGAF1, Elizabeth Kantor, PhD, MPH1, Mengmeng Du, ScD1, Robin B. Mendelsohn, MD1; 1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Digestive Disease Associates, Branford, CT
37. New Technologies Increase Adenoma Detection Rate, Adenoma Miss Rate and Polyp Detection Rate: A Systematic Review and Meta-Analysis
Daniel Castaneda, MD1, Elijah Verheyen, MD1, Praneet Wander, MD2, Violeta Popov, MD, PhD, FACG3, Seth A. Gross, MD4; 1Mount Sinai St. Luke's and Mount Sinai West Hospitals, New York, NY; 2Mount Sinai St. Luke's and Mount Sinai Roosevelt, New York, NY; 3New York University School of Medicine, New York, NY; 4NYU Hospital Center, New York, NY

38. Colorectal Cancer Outcomes in Veterans With Non-advanced Neoplasia
2017 Category Award (Colorectal Cancer Prevention)
Thomas F. Imperiale, MD1, Laura J. Myers, PhD2, Eric A. Sherer, PhD3, and Charles J. Kahi, MD, MSc5, Jason Larson, BS2, David F. Ransohoff, MD6; 1Indiana University School of Medicine, Roudebush VA Medical Center, Indianapolis, IN; 2Roudebush VAMC, Indianapolis, IN; 3Louisiana Tech University, Ruston, LA; 4Indiana University School of Medicine, Indianapolis, IN; 5Indiana University School of Medicine, Roudebush VAMC, Indianapolis, IN; 6University of North Carolina Chapel Hill, Chapel Hill, NC

39. Comparison of Colon Adenoma Detection Rates Using 2 Distal Colonoscope Attachments: A Single Center RCT
2017 Fellows-in-Training Award (Colorectal Cancer Prevention Category)
Joseph Marsano, MD1, Sheeva Johnson, MD, MPH2, Stephanie Yan, MD1, Amar Al Juburi, MD1, Jesse Stondell, MD1, Latifat Ali Akintade, MD1, Machelle Wilson, PhD2, Sooraj Tejaswi, MD, MSPH1; 1University of California Davis Medical Center, Sacramento, CA; 2University of California Davis, Sacramento, CA

40. Prevalence of Mutations in Adenomatous Polyposis and Colorectal Cancer-Associated Genes in Patients With Multiple Colon Polyps Stratified by Age
Peter P. Stanich, MD1, Rachel Pearlman, MS, LGC2, Kory Jasperson, MS3, Alice Hinton, PhD4, Stephanie Gutierrez, BS3, Heather Hampel, MS, LCG1, Carin Espenschied, MS, CGC3; 1The Ohio State University Wexner Medical Center, Columbus, OH; 2The Ohio State University Comprehensive Cancer Center, Columbus, OH; 3Ambry Genetics, Aliso Viejo, CA; 4The Ohio State University College of Public Health, Columbus, OH

ACG’S J. EDWARD BERK DISTINGUISHED LECTURE
Are Our Patients Sleeping Safely and Soundly? The State of Endoscopic Procedural Sedation in 2017
John J. Vargo, II, MD, MPH, FACP
Define the optimal sedation practices for GI endoscopy and review the extended physiologic monitoring techniques and the pharmaeconomic landscape of sedation practice.

SIMULTANEOUS SYMPOSIA SESSIONS

SYMPOSIUM 3A: IBS – Global Issues
Moderators: Lin Chang, MD, FACP, and Greger Lindberg, MD, PhD
Epidemiology and Etiology of Irritable Bowel Syndrome (IBS) Around the World
Max J. Schmulson, MD
Identify the most common etiologies of IBS, including post-infectious causes.

ROME IV vs. Biomarkers: How Accurate Are Our Diagnostic Tools?
William D. Chey, MD, FACP
Differentiate ROME IV criteria from other diagnostic tests for IBS, including serum biomarkers.

Bringing Eastern Therapies to the West
Chun-Ying Wu, MD, MPH, LLM, PhD
Describe complementary and alternative therapies from Asia for IBS and functional gastrointestinal diseases.

SYMPOSIUM 3B: Clinical Dilemmas in IBD Management
Moderators: Jimmy K. Limdi, MD, FACP, and Laura E. Raffals, MD, MS, FACP
Real Challenges in Real Patients: Cases in Crohn’s Disease
David A. Schwartz, MD, FACP
Discuss a typical moderate-to-severe Crohn’s patient and choose appropriate therapies.

Real Challenges in Real Patients: Cases in Ulcerative Colitis
Sunanda V. Kane, MD, MSPH, FACP
Explain the management of a typical moderate-to-severe ulcerative colitis patient and choose appropriate therapies.

Managing Complications and Extra-intestinal Manifestations of IBD and Their Therapies
Paulo Gustavo Kotze, MD, MsC, PhD
Evaluate extra-intestinal manifestations in an IBD patient, such as arthritis or skin eruption, as both a complication of disease and medical therapy.

SYMPOSIUM 3C: Pancreatic Cysts: Much Ado About Nothing?
Moderators: Girish Mishra, MD, MS, FACP, and Luis C. Sabbagh, MD
Natural History of Pancreatic Cysts: What Becomes of Them?
Uzma D. Siddiqui, MD
Appraise the natural history of pancreatic cysts and recognize the risk of malignancy.
EUS of Pancreatic Cysts: What’s New?
Linda S. Lee, MD
Describe the role of EUS in stratifying malignant vs. benign pancreatic cysts.

Another Pancreatic Cyst on CT: Which Guideline Should I Follow?
Jean-Marc Dumonceau, MD, PhD
Formulate an algorithm for pancreatic cyst surveillance.

SYMPOSIUM 3D: The Global State of Hepatitis B: 2017
Moderators: Douglas R. LaBrecque, MD, and Mitchell L. Schiffman, MD, FACG

Global Epidemiology of Hepatitis B: How Is it Acquired and How Can it Be Prevented?
Cihan Yurdagudin, MD
Summarize current global epidemiology, natural history, and clinical course of acute and chronic hepatitis B infection, and review guidelines for HBV vaccination.

Hepatitis B: Who Should Be Treated and With What?
Joseph K. Lim, MD, FACG
Explain current guidelines on the initiation and selection of antiviral therapy for chronic HBV infection, and outline key endpoints for treatment.

Emerging and Future Therapies for Hepatitis B: Is a Cure on the Horizon?
Tram T. Tran, MD, FACG
Describe emerging approaches to novel drug therapy and clinical trial data for hepatitis B, which are aimed at viral eradication.

SIMULTANEOUS PLENARY SESSIONS

SESSION 3A: Interventional Endoscopy
Moderators: Laith H. Jamil, MD, FACG, and Linda S. Lee, MD

41. A Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine versus Rectal Indomethacin Alone for the Prevention of Post-ERCP Pancreatitis in High-Risk Patients
2017 Category Award (Interventional Endoscopy)
Ayesh Kamal, MD1, Venkata Akshinta, MD2, Rupjyoti Talukdar, MD3, Mahesh K. Goenka, DM4, Rakesh Kochhar, DM5, Saroj Sinha, DM5, Rajesh Goud, BSc3, Vijay Kumar, MBBS6, B Joseph Elmunzer, MD7, Mouen Khashab, MD2, Anthony N. Kalloo, MD, FACG2, Duvvuru Nageshwar Reddy, MD, DM, FACG3, Vikesh K. Singh, MD2; 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Johns Hopkins University Hospital, Baltimore, MD; 3Asian Institute of Gastroenterology, Hyderabad, Telangana, India; 4Apollo Gleneagles Hospital, Kolkata, West Bengal, India; 5Postgraduate Institute of Medical Education & Research, Chandigarh, Punjab, India; 6Postgraduate Institute of Medical Education & Research, Kolkata, West Bengal, India; 7Medical University of South Carolina, Charleston, SC

42. Transoral Outlet Reduction for Therapy of Weight Regain After Gastric Bypass
Lucrezia Laterza, MD, Ivo Boskoski, MD, PhD, Rosario Landi, MD, Vincenzo Bove, MD, Guido Costamagna, MD, FACG; Catholic University of Rome, Rome, Lazio, Italy

43. Diagnostic Accuracy of Optical Detection of Residual Colorectal Neoplasia After Endoscopic Mucosal Resection: Impact of Endoclip Closure at EMR Site
Pujaan Kandel, MD1, Eelco C. Brand, MD2, Wei-Chung Chen, MD1, Russell Bingham, BS1, Bhaumik Brahmbhatt, MBBS1, Ernest Bouras, MD1, Victoria Gomez, MD1, Massimo Raimondo, MD1, Michael Wallace, MD1; 1Mayo Clinic, Jacksonville, FL; 2Mayo Clinic, Utrecht, Netherlands

44. A Prospective Multicenter Single-Blind Randomized Controlled Trial Comparing FNA and FNB in the Diagnosis of Solid Masses
Qian Chen, MD, PhD1, Bin Cheng, MD1, Tianan Jiang, MD2, Lizhou Dou, MD3, Jinglin Wang, MD1, Yawen Li, MD1, Yueming Zhang, MD3, Bo Sun, MD4, Hongbo Shan, MD5, Zhuang Deng, MD6, Guoliang Xu, MD5, Xiujiang Yang, MD4, Guiqi Wang, MD3; 1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China; 2The First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China; 3Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China; 4Fudan University Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China; 5Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China; 6The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China

45. Is Alcohol Required for Effective Pancreatic Cyst Ablation? The Prospective Randomized CHARM Trial 2017 Fellows-in-Training Award (Interventional Endoscopy Category)
Matthew T. Moyer, MD, MS, Setareh Sharzehi, MD, Heather D. Heisey, RPh, Thomas J. McGarrity, MD, John M. Levenick, MD, Amanda Cooper, MD, Abraham Mathew, MD, MSC, Jennifer L. Maranki, MD, MS, Niraj Gusani, MD, Brandy D. Headlee, PA-C, Charles E. Dye, MD; Penn State University Milton S. Hershey Medical Center, Hershey, PA

46. Patient-Reported Quality of Life Assessment and Utilization of Health Care After Gastric Peroral Endoscopic Pyloromyotomy (GPOEM)
2017 Fellows-in-Training Award (Interventional Endoscopy Category)
Parit Mekaroonkamol, MD1, Sunil Dacha, MD1, Lei Wang, MD, PhD2, Xiaoyu Li, MD3, Yueping Jiang, MD4, Liangyong Li, MD1, Tian Li, MD5, Nikrad Shahnazav, MD1, Sonali Sakaria, MD6, Francis LeVert, MD1, Steven A. Keilin, MD, FASGE1, Field F. Willingham, MD, MPH1, Jennifer Christie, MD1, Qiang Cai, MD, PhD, FACG1; 1Emory University School of Medicine, Atlanta, GA; 2Department of Gastroenterology, The Hospital, Kolkata, West Bengal, India; 6Postgraduate Institute of Medical Education & Research, Chandigarh, Punjab, India; 5Postgraduate Institute of Medical Education & Research, Kolkata, West Bengal, India; 7Medical University of South Carolina, Charleston, SC
Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China; 3Emory University School of Medicine, Qingdao, Shandong, People's Republic of China; 4The Affiliated Hospital of Qingdao University, Qingdao City, Shandong, People's Republic of China; 5Weihai Municipal Hospital, Weihai, Shandong, People's Republic of China; 6Emory University Hospital, Atlanta, GA

SESSION 3B: Functional GI / Small Bowel
Moderators: Lin Chang, MD, FACG, and Peter R. Gibson, MD

47. A Comparison of the Efficacy and Safety of 2 Dosing Regimens, 2 and 5 Times per Week, of an Intraluminal Vibrating Capsule in the Management of Chronic Idiopathic Constipation
Eamonn M. M. Quigley, MD, MACG1, Michael Camilleri, MD, FACG2, Ron Yishai, MD3, William D. Chey, MD, FACG4, Camille Morriere, MD5, Bharat Misra, MD6, Paula Lane, MD7, Ron Schey, MBB2, Jorge Laredo, DO9, Robert Hardi, MD10, Braden Kuo, MD11, William Nixon, MD12, Dan Keret, MD13, Nimrod Kimchi, MD13, Eran Maoz, MD13, Lili Merdler, MD13, Satish Rao, MD, PhD, FACG14; 1Houston Methodist Hospital, Houston, TX; 2Mayo Clinic, Rochester, MN; 3Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 4Michigan Medicine, Ann Arbor, MI; 5Vibrant Inc., Tel-Aviv, Israel; 6Borland Groover Clinic, Jacksonville, FL; 7Albuquerque Neuroscience, Albuquerque, NM; 8Temple University School of Medicine, Philadelphia, PA; 9Floridian Research Institute, Miami, FL; 10Capital Digestive Care, Chevy Chase, MD; 11Massachusetts General Hospital, Boston, MA; 12Avant Research Associates, Buffalo, NY; 13Clalit Medical Center, Tel-Aviv, Israel; 14Medical College of Georgia/Augusta University, Augusta, GA

48. Efficacy and Safety of Tenapanor in Patients With Constipation Predominant Irritable Bowel Syndrome: A 12-week, Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial
William D. Chey, MD, FACG1, Anthony J. Lembo, MD2, Paul Korner, MD, MBA3, Andrew Yan, PhD3, David P. Rosenbaum, PhD3; 1University of Michigan Health System, Ann Arbor, MI; 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; 3Ardelyx, Inc., Fremont, CA

49. Self-administered Cognitive Behavior Therapy for IBS: The IBS Outcome Study (IBSOS) Randomized Clinical Trial
2017 ACG Governors Award for Excellence in Clinical Research
Jeffrey Lackner, PsyD1, Darren Brenner, MD2, Rebecca Firth, MHA1, Gregory Gudleski, PhD1, Frank Hamilton, MD, MPH3, Leonard Katz, MD1, Laurie Keefer, PhD4, Susan Krasner, PhD1, Chang-Xing Ma, PhD5, Christopher Radziwon, PhD1, Michael Sitrin, MD1, James Jaccard, PhD6; 1University at Buffalo School of Medicine, Buffalo, NY; 2Northwestern University Feinberg School of Medicine, Chicago, IL; 3National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; 4Cahn School of Medicine at Mount Sinai, New York, NY; 5University at Buffalo, Buffalo, NY; 6New York University, New York, NY

2017 Pediatric GI Award
Morris Gordon, MBChB, MMEd, PhD1, Chris Wallace, MBChB2; 1University of Central Lancashire, Preston, United Kingdom; 2Blackpool Teaching Hospitals NHS Trust, Blackpool, United Kingdom

51. The Epidemiology of Celiac Disease in Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, and Eosinophilic Colitis in the United States From 2012 to 2017: Results From a Population-Based National Study
2017 Fellows-in-Training Award (Small Intestine Category)
Emad Mansoor, MD1, Mohannad Abou Saleh, MBBS2, Gregory Cooper, MD3; 1University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; 2University Hospitals of Cleveland, Cleveland, OH; 3University Hospitals Cleveland Medical Center, Cleveland, OH

52. Risk of Autoimmune Endocrinopathies in Treated Celiac Disease Patients in Olmsted County
2017 Category Award (Small Intestine)
Shilpa Nellikkal, MBBS, Joseph Larson, BSc, Joseph A. Murray, MD, Imad Absah, MD; Mayo Clinic, Rochester, MN

ACG'S EMILY COURIC MEMORIAL LECTURE
Colon Cancer: Polyps, Prevention, and Progress
Mark B. Pochapin, MD, FACG
Identify new modalities for the prevention of colon cancer.

WGO'S GEORGES BROHEE LECTURE
News From a Dark Continent – An Assessment of the Diagnostic and Therapeutic Implications of the Gut Microbiome
Eamonn M. M. Quigley, MD, MACG
Recognize clinical contexts where microbiota studies can help to guide patient management.
SIMULTANEOUS SYMPOSIA SESSIONS

SYMPOSIUM 4A: Progress Against Esophageal Cancer
Moderators: Damon B. Bizos, MD, and Prasad G. Iyer, MD, MS, FACG

Global Epidemiology of Esophageal Cancer
Hashem B. El-Serag, MD, MPH
Define the burden of esophageal cancer globally and other epidemiological trends in disease.

Early Detection of Esophageal Cancer and Barrett's Esophagus: Recent Advances
Vitor Arantes, MD, MSc, PhD
Determine strategies to better identify patients at risk for esophageal cancer and Barrett's esophagus.

Progress in the Treatment of Squamous Esophageal Dysplasia and Early-stage Cancer
Kenneth K. Wang, MD, FACG
Discuss new treatment options for early stage cancer and squamous esophageal dysplasia.

SYMPOSIUM 4B: C. difficile and Fecal Microbiota Transplantation (FMT): The Beginnings of Therapeutic Microbiome Management
Moderators: Neil H. Stollman, MD, FACG, and Miguel A. Valdovinos, MD

The Gut Microbiome and Gastrointestinal Disease: Current State of Knowledge
Eamonn M. M. Quigley, MD, MACG
Summarize the current state of the science of the gut microbiome and its relationship to C. difficile infection and other GI illnesses.

FMT for C. difficile: How to Do It and How We are Doing
Monika Fischer, MD, MS
Explain the logistics of performing FMT and the evidence in support of its use in C. difficile infection.

Microbiome Manipulation in IBD, IBS, and Other Disorders
Colleen R. Kelly, MD, FACG
Interpret the evidence for or against the use of microbiome-altering strategies in various GI disorders.

SYMPOSIUM 4C: Biologics for IBD – The End of an Era or Just the Beginning?
Moderators: Peter L. Lakatos, MD, PhD, and Edward V. Loftus, Jr., MD, FACG

Innovator Biologic Therapy: Current and Emerging Biologics for IBD: When, Why, and How
Uma Mahadevan, MD, FACG
Define what innovator biologics are currently available, what will soon be available, and how to choose which one to use.

Biosimilars: What Are They and How Will They Change the Way We Practice?
Peter L. Lakatos, MD, PhD
Explain what biosimilars are and discuss their utilization in practice globally.

Small Molecules: Will Oral Therapy Be the Wave of the Future?
David P. Hudesman, MD
Describe which small molecules have shown promise in trials, and discuss how they could change current IBD treatment algorithms.

SYMPOSIUM 4D: Management of Non-variceal Bleeding
Moderators: David J. Bjorkman, MD, MSPH, FACG, and Seth A. Gross, MD, FACG

I Injected, Clipped, and Burned It, But It Is Still Bleeding: What Do I Do Now?
Alan N. Barkun, MD, CM, MSc (Clinical Epi.), FACG
Discuss therapeutic options and success rates for endoscopic treatment of acute upper GI bleeding.

Who Needs After-hours Endoscopy?
John R. Saltzman, MD, FACG
Outline an algorithm for determining when to perform urgent endoscopy for acute upper GI bleeding.

Wednesday, October 18, 2017

BREAKFAST M: Anorectal Disorders
Moderator: Harry E. Sarles, Jr., MD, FACG

Sensory Disorders: Pruritus, Proctalgia, Incontinence, and Seepage
Arnold Wald, MD, MACG
Identify and describe the evaluation and management of hemorrhoids and fissures.

Incidental Anorectal Neoplasia: Carcinoids, Anal Intraepithelial Neoplasia, and Squamous Cell Carcinoma
Susan Galandiuk, MD, FACG, FACS, FASCRS
Summarize endoscopic and surgical treatment options for common anorectal neoplastic disorders.
BREAKFAST N: Update on Eosinophilic Esophagitis
Moderator: Kathryn A. Peterson, MD, MSCI

**Is There Really a Difference Between PPI Responders and Non-responders?**
Evan S. Dellon, MD, MPH, FACG

Explain the difference between PPI responders and non-responders and whether this makes a difference in management.

**Diet Therapy for Adults: Is it Feasible?**
Kathryn A. Peterson, MD, MSCI

Define when diet therapy is appropriate in the management of EoE.

**Dilation Treatment for EoE: Why Is Everyone so Scared?**
Ikuo Hirano, MD, FACG

Describe when and how to perform dilation in EoE.

---

BREAKFAST O: EUS Beyond Tissue Acquisition: Where the Echoendoscope Wasn't Meant to Be
Moderator: Vivek Kaul, MD, FACG

**Core Biopsies of Solid Lesions: Is This the New Normal? Should We Abandon FNA?**
Luis C. Sabbagh, MD

Appraise the yield of newer biopsy techniques.

**Liver Biopsy Revisited via EUS and Beyond**
Vivek Kaul, MD, FACG

Describe newer techniques and yield for EUS-guided liver biopsy.

**Novel Approaches to Biliary and Pancreatic Drainage**
Duvvur Nageshwar Reddy, MD, DM, Dsc, FAMS, FRCP, FACC, MWGO

Describe and contrast EUS-guided biliary and pancreatic drainage compared to traditional approaches.

---

BREAKFAST P: Advances in the Management of Cirrhosis and Portal Hypertension
Moderator: Nancy S. Reau, MD

**Portal Hypertensive Bleeding: Varices and Beyond**
Norah A. Terrault, MD, MPH, FACG

Describe current medical and endoscopic management of acute esophageal and gastric variceal bleeding, and portal hypertensive gastropathy.

**Hepatic Encephalopathy in Chronic Liver Disease: Occult and Overt**
Nancy S. Reau, MD

Identify current and evolving guidelines for the diagnosis and management of occult and overt hepatic encephalopathy.

**Ascites, Sodium, and Fluid Management**
Nahum Méndez Sánchez, MD, MSc, PhD, FACG

Summarize current guidelines on the management of ascites, hepatic hydrothorax, hyponatremia, and hepatorenal syndrome.

---

SIMULTANEOUS PLENARY SESSIONS

SESSION 4A: Liver
Moderators: Norah A. Terrault, MD, MPH, FACG, and Cihan Yurdaydin, MD

**53. Toxin And Drug-Induced Hepatitis: A Nationwide Analysis of Temporal Trends, Cost of Care and Outcomes**

2017 Fellows-in-Training Award (Liver Category)
Khawa J. Haq, MD1, Shantanu Solanki, MD1, Priyanka Chugh, MD2, Zahava C. Farkas, DO1, Muhammad Ali Khan, MD3, Muhammad Talha Farooqui, MD4, Azam H. Burney5, Shalom Frager, MD1, Dhruv Mehta, MD1, Raja Chandra Chakinala, MD1, Navneet Chawla, MD1, David C. Wolf, MD1; 1New York Medical College at Westchester Medical Center, Valhalla, NY; 2New York Medical College at Westchester Medical Center, New York, NY; 3University of Tennessee Health Science Center, Memphis, TN; 4University of Nevada School of Medicine, Las Vegas, NV; 5Kingsbrook Jewish Medical Center, Brooklyn, NY

**54. Palliative Care in Cirrhosis: Role of Transitional Care Liver Clinic**
Nilofer Najafian, MD1, Jordan Sack, MD1, Angela DeLisle, MHS, PA-C2, Sofia Simona Jakab, MD1; 1Yale University School of Medicine, New Haven, CT; 2Yale New Haven Health, New Haven, CT

**55. Predictors of 30-Day Readmission and Mortality in Patients With Decompensated Liver Cirrhosis: Analysis of Nationwide Readmission Data**
Abdulfatah Issak, MD1, Janel Lee-Allen, MD, MUP2, Khalid Mumtaz, MBBS, MSc2, Kyle Porter, MAS3, James Hanje, MD2, Lanla F. Conteh, MD, MPH2, Anthony J. Michaels, MD2, Sylvester M. Black, MD, PhD2; 1The Ohio State University Wexner Medical Center, Westerville, OH; 2The Ohio State University Wexner Medical Center, Columbus, OH; 3The Ohio State University, Columbus, OH

**56. Changes in Kidney Function and Model for End-Stage Liver Disease Score in Diabetic Patients Undergoing the Transjugular Intrahepatic Portosystemic Shunt Procedure**
Sherwin Chiu, BBA1, Khalid Mahmoud, MD2, Mohamed Shoreibah, MD2, Sherif Moawad, MD, MSc2, Moustafa Massoud, MD2, Steve Kim, BS1, Nathan Ertel, MD2, Rachel Oser, MD2, Souheil Saddekni, MD, FSIR, FAHA2, Andrew Gunn, MD2, Omar Massoud, MD, PhD, FACG2, Basant Hamed, MD2, Ahmed Kamel Abdel Al, MD, MSc, PhD2; 1University of Alabama at Birmingham School of Medicine, Birmingham, AL; 2University of Alabama at Birmingham, Birmingham, AL

**57. Lack of Evidence for Increased Rates of Hepatocellular Carcinoma Following Treatment With Direct Acting Antivirals: A Systematic Review and Meta-Analysis**
Stephanie Rutledge, MBChB, BAO, MRCP, Hui Zheng, PhD, Darrick K. Li, MD, PhD, Raymond T. Chung, MD; Massachusetts General Hospital, Boston, MA
58. Assessment of Potential Impact of Demographic and Baseline Disease Characteristics on Rifaximin Monotherapy versus Lactulose Combination Therapy for the Prevention of Overt Hepatic Encephalopathy (OHE) Recurrence
Steven Flamm, MD1, Kevin Mullen, MD2, Zeev Heimanson, PharmD3, Arun Sanyal, MD4; 1Northwestern University Feinberg School of Medicine, Chicago, IL; 2MetroHealth Medical Center, Cleveland, OH; 3Salix Pharmaceuticals, Bridgewater, NJ; 4Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA

59. MELD Score Predicts Fungal Infections in Acute-on-Chronic Liver Failure Patients
Sanjeev Yarlagadda, MD1, Nehali Patel, MD2, Chiu-Hsieh Hsu, PhD3, Courtney Walker, DO4, Sarah Patel, MD5, Shahid Habib, MD6; 1Tucson Medical Center, Tucson, AZ; 2Kaiser Permanente, Fontana, CA; 3University of Arizona, Tucson, AZ; 4University of Utah, Salt Lake City, UT; 5University of Washington, Seattle, WA; 6Liver Institute, Tucson, AZ

60. Effect of Obeticholic Acid Treatment in Patients With Primary Biliary Cholangitis on Categorical Shifts in GLOBE Score
Maren H. Harms, PhD1, Willem J. Lammers, PhD2, Bettina E. Hansen, MSc3, PhD3, Marlyn J. Mayo, MD4, Albert Pares, MD5, Elizabeth Smoot Malecha, PhD6, Richard Pencek, PhD6, Leigh MacConell, PhD6; 1Erasmus University Medical Center, Rotterdam, Zuid-Holland, Netherlands; 2Erasmus University Medical Centre, Rotterdam, Zuid-Holland, Netherlands; 3University of Toronto, Toronto, ON, Canada; 4UT Southwestern Medical Center, Dallas, TX; 5University of Barcelona, Barcelona, Spain; 6Intercept Pharmaceuticals, Inc., San Diego, CA

61. Early Prediction of Variceal Hemorrhage in Upper Gastrointestinal Bleeding
Brandon J. Teng, MD1, Stephen Bach2, Anand C. Baxi, MD1, Michael A. Harms, MD1, Elisabeth Jensen-Otsu, MD1, Cynthia W. Ko, MD, MS2, Lisa L. Strate, MD, MPH, FACG3; 1University of Washington Medical Center, Seattle, WA; 2University of Washington, Seattle, WA; 3University of Washington School of Medicine, Seattle, WA

SESSION 4B: Esophagus/Colon
Moderators: Christine Y. Hachem, MD, FACG, and Carmelo Scarpignato, MD, DSc, FRCP, FACG

63. Elective Colectomy for the Treatment of Benign Colon Polyps: National Surgical Trends, Outcomes and Cost Analysis
Luke Martin, MD1, Jessica X. Yu, MD2, Andrew Gawron, MD, PhD1, Benjamin Brooke, MD, PhD1, William Peche, MD, MSPH1, Tonya Kaltenbach, MD, MS3; 1University of Utah School of Medicine, Salt Lake City, UT; 2Stanford University School of Medicine, Stanford, CA; 3San Francisco VA Medical Center, San Francisco, CA

64. The Risk Predictive Values of ACG Classification in a Cohort of Colon Ischemia: Refining the Definition of Mild Disease
Vítor Magno Pereira, MD1, Carolina Simões, MD2, Marco Silva, MD3, Joana Carvão, MD1, António Oliveira, MD4, Célia Baldaia, MD5, Goreti Serrão, MD1, Luís Jasmim, MD1, José Velosa, MD5; 1Centro Hospitalar do Funchal, Funchal, Madeira, Portugal; 2Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal; 3Department of Gastroenterology - Centro Hospitalar de São João, Porto, Portugal; 4Centro Hospitalar do Funchal, Funchal, Madeira, Portugal; 5Centro Hospitalar Lisboa Norte, Medical School of Lisbon, Lisbon, Portugal

65. Fecal Microbiota Transplant Decreases Mortality in Patients With Severe and Severe-Complicated Clostridium difficile Infection, Including Cases Not Eligible for Colectomy
2017 Fellows-in-Training Award (Colon Category)
Yao-Wen Cheng, MD1, Emmalee Phelps, BS2, Nicholas Rogers, MD2, Sashidhar Sagi, MBBS2, Matthew Bohm, DO2, Mustapha El-Halabi, MD1, Jessica Allegretti, MD, MPH3, Zain Kassam, MD, MPH4, Huiping Xu, PhD5, Monika Fischer, MD, MSc6; 1Indiana University School of Medicine, Indianapolis, IN; 2Indiana University Medical Center, Indianapolis, IN; 3Brigham & Women’s Hospital, Boston, MA; 4OpenBiome, Somerville, MA; 5Indiana University–Purdue University Indianapolis, Indianapolis, IN

66. Low Resolution rates in Open-Label and Randomized Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis
Raseen Tariq, MBBS, Darrell S. Pardi, MD, MS, Mark Bartlett, MD, Sahil Khanna, MBBS, MS; Mayo Clinic, Rochester, MN

Mohammad Alshelleh, MD1, Sumant Inamdar, MD, MPH2, Dennis Han, MD3, Jeffrey Novak, MD4, Keith Sultan, MD, FACG5; Bethany Devito, MD, FACG6, Mary Cheung, MD7, Petros Benias, MD8, Divyesh V. Sejpal, MD2, Matthew McKinley, MD, FACG, FACP9, Arvind Trindade, MD10; 1Hofstra Northwell School of Medicine, Northwell Health System, Bronx, NY; 2Hofstra Northwell School of Medicine, Manhasset, NY; 3Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY; 4Northwell University Hospital, Manhasset, NY; 5Northwell Health, Great Neck, NY; 6Northwell Hofstra School of Medicine, Great Neck, NY; 7Hofstra North Shore-LIJ School of Medicine, Northwell Health System, Great Neck, NY; 8Hofstra North Shore-LIJ School of Medicine, Manhasset, NY; 9ProHealth Care Associates, Lake Success, NY; 10Long Island Jewish Medical Center, New Hyde Park, NY
68. Defining the Rates of Missed and Interval High-Grade Lesions in Patients With Barrett’s Esophagus: Results From a Large Multicenter Study
Sravanthi Parasa, MD, MPH1, Sreekar Vennelaganti, MD2, Patrick Young, MD3, Prashanthi Vennalaganti, MD4, Ajay Bansal, MD5, Srinivas Gaddam, MD6, Neil Gupta, MD7, Richard Sampliner, MD8, Gary Falk, MD9, Prashanthi N. Thota, MD10, Sharad Mathur, MD11, Brooks D. Cash, MD, FACG12, Moawad Fouad, MD3, John Vargo, MD10, Kevin Kennedy, MS2, Sophie Van Olphen, MD13, Manon Spaander, MD13, Marco Bruno, MD13, Prateek Sharma, MD2; 1Case Western Reserve University School of Medicine, Cleveland, OH; 2Kansas City VA Medical Center, Kansas City, MO; 3Gastroenterology, Walter Reed National Military Center, Bethesda, MD; 4Gastroenterology, Kansas City VA Medical Center, Kansas City, MO; 5University of Kansas Medical Center, Kansas City, KS; 6Gastroenterology, Cedars Sinai Medical Center, Los Angeles, CA; 7Loyola University, Maywood, IL; 8Gastroenterology, University of Arizona, Tucson, AZ; 9Hospital of the University of Pennsylvania, Philadelphia, PA; 10Cleveland Clinic Foundation, Cleveland, OH; 11University of Kansas, Kansas City, KS; 12University of South Alabama College of Medicine, Mobile, AL; 13Erasmus Medical Centre, Rotterdam, Netherlands

69. Esophageal Adenocarcinoma in a First Degree Relative Increases the Risk for Progression to Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus
2017 Fellows-in-Training Award (Esophagus Category) Christina Toﬁni, MD1, Kunjal Gandhi, MD2, Joseph Spataro, MD2, Joseph Yoo, MD3, Megan Murphy, MD2, Neena Mohan, MD2, Zachary Daitch, MD4, Apeksha Shah, MD2, Raymond Janowski, MD2, Noreen Dabbish, MS5, Scott Keith, PhD5, David Kastenberg, MD2, Robert M. Cohen, MD5, Sidney Cohen, MD2, Anthony Infantolino, MD6; 1Thomas Jefferson University Hospital, Pennsauken, NJ; 2Thomas Jefferson University Hospital, Philadelphia, PA; 3Thomas Jefferson University Hospital, Drums, PA; 4Sidney Kimmel Medical College at Thomas Jefferson University, Bala Cynwyd, PA; 5Thomas Jefferson University, Philadelphia, PA; 6Thomas Jefferson University Medical Center, Philadelphia, PA

70. Effect of Opiates on Esophageal Function Testing in Patients With Non-cardiac Chest Pain
Juan D. Gomez Cifuentes, MD; Cleveland Clinic Foundation, Cleveland, OH

71. Following Peroral Endoscopic Myotomy (POEM) Gastroesophageal Reflux (GERD) Is Frequent and Is Associated With Increased Esophagogastric Junction Distensibility Measured by EndoFLIP
Jennifer Horsley-Silva, MD, Norio Fukami, MD, Michael D. Crowell, PhD, MACG, AGAF, Marcelo Vela, MD; Mayo Clinic, Scottsdale, AZ

72. Comparison Between Submucosal Tunneling Endoscopic Resection and Video-Assisted Thoracoscopic Enucleation for Esophageal Submucosal Tumors Originating From the Muscularis Propria Layer: A Randomized Controlled Trial
Chen Du, MS, Ningli Chai, MD, PhD, Ying Gao, MM, Xiaotong Niu, MM, Yaqi Zhai, MM, Enqi Qing Linghui, MD, PhD, Yang Liu, MD, PhD, Bo Yang, MD, Zhongsheng Lu, MD, Xiangdong Wang, MB, Ping Tang, MB; Chinese PLA General Hospital, Beijing, People’s Republic of China

SESSION 4C: IBD
Moderators: Sunanda V. Kane, MD, MSPH, FACG, and Shabana F. Pasha, MD

73. A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn’s Disease: Data From CALM
2017 ACG Governors Award for Excellence in Clinical Research
Jean-Frederic Colombel, MD1, Remo Panaccione, MD, FRCPC2, Peter Bossuyt, MD3, Filip Baert, MD4, Tomas Vanasek, MD5, Ahmet Danaloglugi, MD6, Gottfried Novacek, MD7, Alessandro Armuzzi, MD8, Xavier Hebuterne, MD9, Simon Travis, MD10, Silvio Danese, MD11, Walter Reinisch, MD12, William J. Sandborn, MD13, Paul Rutgeerts, MD14, Daniel Hommes, MD15, Stefan Schreiber, MD16, Ezequiel Neimark, MD17, Bidan Huang, MD17, Qian Zhou, MD17, Wan-Ju Lee, MD17, Joel Petersson, MD17, Kori Wallace, MD17, Anne M. Robinson, MD17, Roopal B. Thakkar, MD17, Geert D’Haens, MD, PhD18; 1Cahn School of Medicine at Mount Sinai, New York, NY; 2University of Calgary, Department of Medicine, Calgary, AB, Canada; 3Imelda General Hospital, Bonheiden, Antwerpen, Belgium; 4AZ Delta Roeselare-Menin, Menin, Antwerpen, Belgium; 5Hepato-Gastroenterologie HK, Hradec Králové, Czech Republic; 6Bzmiadm Vakif University, Istanbul, Turkey; 7Medical University of Vienna, Vienna, Austria; 8Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Lazio, Italy; 9Service de Gastroentérologie et Nutrition Clinique, Université de Nice-Sophia-Antipolis, Nice, Provence-Alpes-Cote d’Azur, France; 10Oxford University Hospitals, Oxford, United Kingdom; 11Istituto Clinico Humanitas, Milan, Italy; 12Medical University of Vienna, Hamilton, ON, Canada; 13University of California, La Jolla, CA; 14University of Leuven, Leuven, Belgium; 15University of California Los Angeles, Los Angeles, CA; 16University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany; 17AbbVie, Inc., North Chicago, IL; 18Academic Medical Center, Amsterdam, Noord-Holland, Netherlands

74. A Novel Serum Test to Describe the Mucosal Healing State by Disease Location in Crohn’s Disease Patients
Séverine Vermeire, MD, PhD1, Geert D’Haens, MD, PhD2, Michael Hale, PhD3, Venkateswarlu Kondragunta, PhD3, Kurt Bray, PhD3, Anjali Jain, PhD3, David Laharie, MD, PhD4; 1University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium; 2Academic Medical Center, Amsterdam, Noord-Holland, Netherlands; 3Prometheus Laboratories, Inc., San Diego, CA; 4CHU de Bordeaux, Pessac, France
75. Trends of Infection Prevalence in Inflammatory Bowel Disease and Effect on Hospitalization Outcomes: A U.S. Perspective 2005-2014
2017 Fellows-in-Training Award (IBD Category)
Paris Charilaiou, MD, Kalpit Devani, MD2, Chakradhar M. Reddy, MD3, Mark Young, MD3, Debra Goldstein, MD4; 1Saint Peter’s University Hospital, New Brunswick, NJ; 2James H. Quillen College of Medicine, East Tennessee University, Johnson City, TN; 3East Tennessee State University, Johnson City, TN; 4Saint Peter’s University Hospital, New Brunswick, NJ

76. Biologic Therapy in Pediatric Inflammatory Bowel Disease: Can We Influence the Natural History of the Disease After Suspension of the Treatment? Preliminary Results
Federica Gaiani, MD1, Silvia De Bonis, MD2, Fabiola Fornaroli, MD2, Carmen Madia, MD2, Silvia Iuliano, MD2, Alessia Ghiselli, MD2, Barbara Bizzarri, MD2, Francesca Vincenzi, MD2, Gian Luigi de’Angelis, MD, PhD2; 1University Hospital of Parma, Parma, Emilia-Romagna, Italy; 2University Hospital of Parma, Parma, Emilia-Romagna, Italy

77. Recurrence of Non-melanoma Skin Cancer in Inflammatory Bowel Disease Patients Who Continue Thiopurines After Developing Incident Non-melanoma Skin Cancer While on a Thiopurine
Yash Shah, MD1, Chhinmay Trivedi, MD2, Nabeel Khan, MD2, 1VA Hospital Philadelphia, Philadelphia, PA; 2Philadelphia VA Medical Center, Philadelphia, PA

78. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
Kevin L. Winthrop, MD, PhD1, Gil Y. Melmed, MD, MS2, Séverine Vermeire, MD, PhD3, Millié D. Long, MD, MPH4, Gary Chan, PharmD, MS5, Ronald D. Pedersen, MS6, Nervin Lawandy, PharmD6, Andrew J. Thorpe, PhD6, Chudy I. Nduaka, DVM, PhD6, Chinyu Su, MD6; 1Oregon Health and Science University, Portland, OR; 2Cedars-Sinai Medical Center, Los Angeles, CA; 3University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium; 4University of North Carolina, Center for Gastroenterological Disease and Disease, Chapel Hill, NC; 5Pfizer Inc., Groton, CT; 6Pfizer Inc., Collegeville, PA

79. Workflow Algorithm Changes for Triaging IBD Outpatient Calls Can Improve Patient Experience and Reduce Physician Burden
Tenzin Choden, MD1, Anand Nath, MD2, Melissa O’Hara, RN1, Aimee LeStrange, CRNP1, Tamira Sanni-Sanoussi, MD1, Mark C. Mattar, MD, FACG1; 1MedStar Georgetown University Hospital, Washington, DC; 2MedStar Washington Hospital Center, Washington, DC

Bijn J. Kannadath, MBBS, Matthew Merwether, MD, MBA, Andrew Herman, MD, Harsh D. Patel, MD, James Stone, MD, Danielle M. Stone, MD, Nirav C. Thosani, MD, MHA, Sushovan Guha, MD, PhD; University of Texas Health Science Center at Houston, Houston, TX

81. eConsultation to Gastroenterology Specialists: Questions Asked and Cost Saved
Jennifer Wang, MD1, Kimberly Dowdell, MD2, Anne G. Tuskey, MD3, Ann R. Hays, MD2; 1University of Virginia, Charlottesville, VA; 2University of Virginia Health System, Charlottesville, VA; 3University of Virginia Digestive Health Center, Charlottesville, VA

82. One-year Efficacy and Safety of a Single Dose of Cx601, Allogeneic Expanded Adipose-Derived Mesenchymal Stem Cells, for Complex Perianal Fistulas in Crohn’s Disease: Long-Term Results of a Phase 3, Randomized, Double-Blind Clinical Trial
Daniel C. Baumgart, MD, PhD1, Julián Panés, MD2, Damián García-Olmo, MD3, Gert Van Assche, MD, PhD4, Jean F. Colombel, MD5, Walter Reinisch, MD6, María Nachury, MD7, Marc Ferrante, MD, PhD4, Lili Kazemi-Shirazi, MD6, Jean C. Grimaud, MD8, Fernando de la Portilla, MD9, Eran Goldin, MD10, Marie Paule Richard, MD11, Ignacio Tagarro, PhD11, Silvio Danese, MD, PhD12; 1Charité Medical School - Humboldt-University of Berlin, Berlin, Germany; 2Hospital Clinic Barcelona, Barcelona, Spain; 3Hospital U. Fundación Jiménez-Díaz, Madrid, Spain; 4University Hospitals Leuven, KU Leuven, Leuven, Belgium; 5Cahm School of Medicine at Mount Sinai, New York, New York, USA; 6Medical University of Vienna, Vienna, Austria; 7Centre Hospitalier Régional Universitaire (CHRU) de Lille, Lille, France; 8Hôpital Nord, Marseilles, France; 9Hospital Virgen del Rocio, Seville, Spain; 10Sharee Zedek Medical Center, Jerusalem, Israel; 11TiGenix, Madrid, Spain; 12Istituto Clinico Humanitas, Milan, Italy

SESSION 4D: Best of Original Latin American Research Moderators: Carolina Olano, MD, MSc (Ed), and Flavio Steinwurz, MD, MSc, MACG

LA1. In vivo Detection of Colonic Mucosa Microinflammation by Confocal Laser Endomicroscopy Probe (p-CLE) in Patients With Irritable Bowel Syndrome (Oral 6)
2017 Category Award (Functional Bowel Disease)
Carlos Robles-Medranda, MD, Manuel Valero, MD, Miguel Soria-Alcivar, MD, Miguel Puga-Tejada, MD, MSc, Jesenia Ospina-Arboleda, MD, MSc., Haydee Alvarado-Escobar, MD, Guillermo Munoz-Jurado, MD, Roberto Oleas, Hannah Pitanga-Lukashok, MD, Ecuadorian Institute of Digestive Diseases, Guayaquil, Guayas, Ecuador

LA2. Aggressive Hydration With Lactated Ringer’s Solution versus Saline Solution to Reduce the Risk of Pancreatitis Post-ERCP (Poster 517)
2017 Presidential Poster Award
Marcelo Alcivar-Leon, MD1, Ivan Nieto-Orellana, MD2, Maria Luisa Jara-Alba, MD3, Eduardo Marriott-Diaz, MD3, Andres Serrano-Suarez, MD3, Manuel Guaranda-Maya, MD3, Noelia Garzon-Cercado, MD3, Monica Caballero-Giler, MD3, Luis Aynaguano-Colcha, MD3, Fausto Moreno-Brones, MD2, Alexandra Gallegos-Lozano, MD3, Ernesto Paladines-Paladines, MD2, Kleber Ramirez-Oyola, MD2, Lucia Hernandez-Ludena, MD2, Cristina Arboleda-Saavedra, MD2, Arturo Carpio-Guerrero,
LA3. Degree of Estimated Fibrosis in Asymptomatic Subjects With Non-Alcoholic Fatty Liver Disease Correlates With Higher Cardiovascular Risk (Oral 12)
Maria Cristina Moreno del Castillo, MD, Alain Sanchez Rodriguez, MD, Javier Jose Hernandez Buen Abad, MD, Jose Ramon Mena Ramirez, MD, Maria Emilia Mendizabal Rodriguez, MD, Jonathan Salazar Segovia, MD, Ignacio Garcia Juarez, MD; American British Cowdray, Medical Center, Mexico City, Distrito Federal, Mexico

LA4. Clinicopathological Characteristics and Prognostic Value of Epstein-Barr Virus-associated Gastric Cancer, Microsatellite Instability and PD-L1 Immunoeexpression (Poster 804)
Marina Alessandra Pereira, MSc1, Marcus Fernando Kodama Pertille Ramos, MD, MSc1, Andre Roncon Dias, MD, PhD1, Sheila Friedrich Faraj, MD1, Osmar Kenji Yagi, MD, PhD1, Bruno Zilberstein, MD, PhD1, Ivan Ceconello, MD, PhD1, Evandro Soboza de Mello, MD, PhD2, Ulysses Ribeiro, Jr., MD, PhD1; 1University of Sao Paulo School of Medicine, Sao Paulo, Brazil; 2University of Sao Paulo, Sao Paulo, Brazil

LA5. Non-alcoholic Fatty Pancreas Disease Is Associated With Prediabetes in Hispanics (Poster 1725)
Javier Jose Hernandez Buen Abad, MD, Maria Cristina Moreno del Castillo, MD, Alain Sanchez Rodriguez, MD, Maria Emilia Mendizabal Rodriguez, MD, Jonathan Salazar Segovia, MD, Ricardo Garcia-Buen-Abad, MD, Natalie Atkinson, MD, Ignacio Garcia Juare, MD; American British Cowdray, Medical Center, Mexico City, Distrito Federal, Mexico

LA6. Colonoscopic Findings in Patients With Positive Fecal Immunochemical Test During a Pilot Study of Colorectal Cancer Screening in a Western Country: Partial Results (Poster 180)
Mauricio P. Sorbello, MD1, Ulysses Ribeiro, Jr., MD, PhD2, Victor Rossi Bastos Bastos, MD1, Vinicius Pflutenreiter, MD1, Afonso Henrique Sousa Jr, MD, PhD1, Diane Cohen, NP1, Venancio Avancini Alves, MD, PhD1, Claudio Hashimoto, MD, PhD1, Sergio Nahas, MD, PhD1, Ivan Ceconello, MD, PhD2, Jose Eluf Neto, MD, PhD1, Adriana Vaz Safatle-Ribeiro, MD, PhD1; 1University of Sao Paulo, Sao Paulo, Brazil; 2University of Sao Paulo School of Medicine, Sao Paulo, Brazil

LA7. Study of Effectiveness of Liposomal Oral Rehydration Solutions in an Osmotic Diarrhea Model in Rats (Poster 699)
Alejandro Barbarini, MSCI; Universidad Nacional del Litoral, Santa Fe, Argentina

LA8. Bipolar Electrocoagulation Therapy, BICAP, for Treatment of Post-Radiation Proctitis (Poster 112)
Edson Jurado da Silva, MD, FACP; Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil

LA9. Esophageal Carcinoma: A 20-Year Cohort Study (Poster 1071)
Patricio Ortiz, MD, FACP, Francisco Henriquez, MD; Universidad de Concepcion, Concepcion, Bio-Bio, Chile

LA10. Evaluation of the Use of Vedolizumab in 46 Patients With Inflammatory Bowel Disease in Brazil (Poster 2184A)
Flavio Steinwurz, MD, MSc, MACG, Nayara Salgado Carvalho, MD, Fernando Seefelder Falquer, MD; Hospital Israelita Albert Einstein, Sao Paolo, Brazil

ACG’S DAVID Y. GRAHAM LECTURE
On Becoming a Successful Leader: An Amazing Journey or the Road to Nowhere?
Sunanda V. Kane, MD, MSPH, FACP
Recognize the attributes and tools necessary to become a successful leader for any scenario.

SIMULTANEOUS SYMPOSIA SESSIONS

SYMPOSIUM 5A: Approaches to Acute and Chronic Diarrhea
Moderators: Maria T. Abreu, MD, and Michael J.G. Farthing, MD

Diagnosis and Prevention of Acute Diarrhea: What Do the Guidelines Say?
Bradley A. Connor, MD
Identify the value of diagnostic tests and prevention strategies for acute diarrhea.

Management of Acute Diarrhea in Adults: A Global Perspective
Michael J.G. Farthing, MD
Discuss the management of acute diarrhea in adults, comparing differences in developed versus developing countries.

A Practical Approach to the Work-up of the Patient With Chronic Diarrhea
Amy S. Oxentenko, MD, FACP
Describe a step-wise approach to the work-up of chronic diarrhea based on disease prevalence.
SYMPOSIUM 5B: Quality and Technique in Colonoscopy
Moderators: Joseph C. Anderson, MD, MHCDS, FACG, and Roland Valori, MD, MB BS, FRCP, MSc (Oxon), ILTM

Quality Metrics of Colonoscopy
Irving M. Pike, MD, FACG
Categorize the different quality metrics for colonoscopy, how and what to measure, and what to report.

Building a Better Colonoscopist: Improving Quality With Technique and Technology
Evelien Dekker, MD, PhD
Analyze tools and techniques for improving colonoscopic quality.

Serrated Polyps: Recognize, Remove, Risk Stratify
Tonya R. Kaltenbach, MD, MS, FACG
Discuss strategies to recognize, remove, and risk stratify serrated polyps.

SYMPOSIUM 5C: Controversies in GERD
Moderators: Naïma Amrani, MD, and Samir A. Shah, MD, FACG

Does Extra-esophageal GERD Exist, and If So, Why Can’t I Find It?
Abraham R. Khan, MD
Identify how to define and approach patients presenting with extra-esophageal GERD symptoms.

What Afflicts PPI Non-responders, and How Do I Treat Them?
Philip O. Katz, MD, MACG
Discuss how to better categorize PPI non-responders and tailor therapy based on physiologic phenotypes.

What Are the Real Adverse Effects of PPIs?
Paul Moayyedi, MBChB, PhD, MPH, FACG
Define the real risks of PPI therapy and how to communicate them to our patients.

SYMPOSIUM 5D: Global Education: WGO
Moderators: David J. Bjorkman, MD, MSPH, FACG, and Guilherme G. Macedo, MD, PhD, FACG

WGO Training Centers: Developing an Endoscopy Service in Limited Resource Settings
Desmond J. Leddin, MB, MSc, FRCPc, FRCPI
Discuss how to start and sustain endoscopy services in settings with limited resources.

WGO Train the Trainers: How Can I Improve my Teaching Skills?
Damon B. Bizos, MD
Recognize ways to improve lectures, small group facilitation, and teaching skills.

WGO Guidelines: Why Cascades?
Greger Lindberg, MD, PhD
Describe the use of the Guidelines Cascades Model and the application of WGO Guidelines in regions of variable resources.